Home Help [For Subscribers] [Archive] Institution: || Sign In as Individual


Blood First Edition Paper prepublished online August 8, 2002; DOI 10.1182/blood-200112-0349
Blood, 15 December 2002, Vol. 100, No. 13, pp. 4272-4290 REVIEW ARTICLE Reprint (PDF) Version of this Article Email this article to a friend Similar articles found in: Blood Online PubMed PubMed Citation Search Medline for articles by: Spivak, J. L. Alert me when: new articles cite this article Download to Citation Manager Collections under which this article appears: Review Articles Clinical Observations, Interventions, and Therapeutic Trials Hematopoiesis Neoplasia All Versions of this Article: 100/13/4272 (most recent) 2001-12-0349v1

Polycythemia vera: myths, mechanisms, and management
Jerry L. Spivak From the Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Polycythemia vera is a clonal disorder arising in a multipotent hematopoietic progenitor cell that
Top Introduction The pathogenesis of... The diagnosis of polycythemia...

causes the accumulation of morphologically normal red cells, white cells, platelets, and their progenitors in the absence of a definable stimulus and to the exclusion of nonclonal hematopoiesis.1,2 First described in 1892,3 polycythemia vera is not a new disease and while uncommon, with an incidence of at least 2 per 100 000,4-6 it is not a rare disease. Yet, after 10 decades of careful clinical and laboratory investigation, the etiology of polycythemia vera remains unknown and there is no consensus as to the optimal therapy for the disorder. 7 There is, however, no reason for this to be so. Although the molecular basis of polycythemia vera remains elusive, it is the central thesis of this review that the pathophysiology of polycythemia vera is sufficiently well defined for the provision of a rational treatment program that prolongs life, alleviates the specific morbidities associated with the disease, and avoids complications related to the consequences of the underlying molecular defect. However, for such an approach to be successful, it is first necessary to recognize the contradictions between what is actually known about this disease and how that knowledge has been interpreted and applied clinically, and that is the purpose of this review.

The diagnosis of polycythemia... Anecdote as paradigm: the... Survival with polycythemia... Phlebotomy and polycythemia... Thrombocytosis and polycythemia... The management of polycythemia... References

The pathogenesis of polycythemia vera: polycythemia vera is a myeloaccumulative disorder not a myeloproliferative disorder
Erythropoiesis and growth factor hypersensitivity
Top Introduction The pathogenesis of... The diagnosis of polycythemia... Anecdote as paradigm: the... Survival with polycythemia... Phlebotomy and polycythemia... Thrombocytosis and polycythemia... The management of polycythemia... References

Because it involves a multipotent hematopoietic progenitor cell, the hallmark of polycythemia vera is trilineage hematopoietic cell hyperplasia. However, erythrocytosis is its most prominent clinical manifestation, the cause of its most serious complications, and the "sine qua non" for its diagnosis. Therefore, most investigations of the pathogenesis of polycythemia vera have focused on

erythropoiesis but with paradoxical results. Red cell life span is not prolonged in polycythemia vera8 and the erythroid progenitor cell pool is not expanded at the expense of the myeloid progenitor cell pool. 9 At the same time, neither hyperoxia10 nor renal failure11 suppress erythropoiesis in polycythemia vera patients, phlebotomy does not stimulate it,12,13 and serum erythropoietin levels are lower than in any other disease 14 (Figure 1). Figure 1. Relationship between serum erythropoietin and hemoglobin in patients with polycythemia vera ( ), secondary erythrocytosis ( ) or relative erythrocytosis (x). Adapted from Handin et al369 with permission of the publisher, Lippincott, Williams, and Wilkins.

View larger version (11K): [in this window] [in a new window]

These paradoxical results are due to the ability of polycythemia vera erythroid progenitor cells to proliferate in vitro in the absence of erythropoietin.15 This unusual behavior, however, does not define the limits of the abnormal clone since not all polycythemia vera erythroid progenitor cells exhibit erythropoietin-independence in vitro. 16,17 Importantly, primitive polycythemia vera erythroid progenitor cells exhibiting either erythropoietin-dependence or -independence could give rise to both erythropoietin-dependent and -independent progeny, a characteristic that appeared fixed given that it remained constant over time when these progenitor cells were cultured in vitro. It is also worth noting that the in vitro proliferation of polycythemia vera erythroid progenitor cells in the absence of erythropoietin was not robust.17 This may be a consequence of the tendency of these cells to differentiate faster in vitro than normal erythroid progenitor cells in the absence of erythropoietin.18 Thus, the dominance exerted by the polycythemia vera erythroid clone over polyclonal erythroid precursors2 could be due in part to its ability to complete its differentiation more efficiently in a low erythropoietin milieu.

This dominance may also involve transforming growth factors produced by polycythemia vera mononuclear cells 19 and the hypersensitivity of polycythemia erythroid progenitor cells to interleukin 3 (IL-3), granulocyte macrophage-colony-stimulating factor (GM-CSF),20 stem cell factor (SCF), 21 and insulinlike growth factor (IGF-1). 22 Despite claims to the contrary, 23,24 this hypersensitivity does not appear to be the consequence of an abnormality in the negative regulatory hematopoietic phosphatase, SHP-1.25,26 Indeed, evidence has been obtained for increased activity of a membrane-associated protein tyrosine phosphatase in polycythemia vera erythroid progenitor cells 27 and although overexpression of INK4a and ARF has also been documented in these cells 28 and constitutive phosphorylation of STAT3 has been observed in the granulocytes in a minority of patients,29 no consistent abnormality of signal transduction or cell cycle regulation has been identified to date in polycythemia vera nor have mutations been identified in p53 or Ras during the chronic phase of the illness.30 There is evidence for both gain31,32 and loss33,34 of suppressor genes in polycythemia vera but exactly which genes and how they might affect erythroid progenitor cell behavior remain unknown. Erythropoietin receptor function Given the ability of polycythemia vera erythroid progenitor cells to survive in vitro in the absence of erythropoietin as well as their hypersensitivity to erythropoietin in particular and hematopoietic growth factors in general, there has been substantial interest in growth factor receptor function in this disease. c-Kit expression, ligand affinity, and internalization were normal in polycythemia vera erythroid progenitor cells 35 but the development of erythropoietin hypersensitivity or independence as a consequence of gain in function mutations in the ligand-binding and cytoplasmic domains of the erythropoietin receptor 36 raised the possibility that this receptor was involved in the pathogenesis of the disease. However, erythropoietin receptor expression and ligand binding were not different in polycythemia vera erythroid progenitor cells compared with normal erythroid progenitor cells. 37,38 Furthermore, no erythropoietin receptor gene amplification, rearrangements, or functional mutations have been identified in polycythemia vera patients.39 This is not surprising because forced expression of the

erythropoietin receptor in primitive hematopoietic stem cells did not induce autonomous proliferation, enhance progenitor cell renewal, or stimulate granulopoiesis, 40 all of which are features of polycythemia vera. Furthermore, although expression of a constitutively-active erythropoietin receptor caused both erythrocytosis and thrombocytosis in vivo, 41 it did not cause trilineage hematopoietic progenitor cell hyperplasia. Alternatively spliced forms of the erythropoietin receptor have been identified, one of which has a truncated cytoplasmic domain and was expressed at high levels in immature erythroid progenitor cells in contrast to the full-length receptor, expression of which increased with progenitor cell maturation. 42 The function of the truncated receptor splice variant has been a matter of controversy.43,44 It was incapable of transmitting a signal but interfered with the proliferative activity of the full-length erythropoietin receptor 44 while promoting differentiation. 45 The truncated erythropoietin receptor splice variant was either not expressed well or at all in various erythroleukemia cell lines 42,46 and its expression was also decreased or absent in polycythemia vera mononuclear cells. 46 Since polycythemia vera erythroid progenitor cells differentiate more quickly than their normal counterparts, 18 the significance of these observations with respect to the pathophysiology of the disease remains to be established. Programmed cell death The diverse and often conflicting observations concerning the behavior of polycythemia vera erythroid progenitor cells can be reconciled by the recent recognition that polycythemia vera erythroid progenitors overexpressed the antiapoptotic protein Bcl-xl and were resistant to apoptosis in the absence of erythropoietin.47 Under normal circumstances, early erythroid progenitor cells are largely dormant and require erythropoietin as a mitogen to initiate their entry into cell cycle,48 while late erythroid progenitor cells which are largely cycling require only erythropoietin as a survival factor to allow completion of terminal differentiation. 49 Erythropoietin deprivation results in cell cycle arrest in G0 /G1 ,50 and down-regulation of expression of the antiapoptotic proteins Bcl-2 and Bcl-xl followed by programmed cell death.51 By contrast, overexpression of Bcl-2 or Bcl-xl allowed

erythroid progenitor cells to maintain their viability while undergoing terminal differentiation in the absence of erythropoietin.51 This behavior is not unique to erythroid progenitor cells, since multipotent hematopoietic progenitor cells overexpressing Bcl-2 not only remained viable in the absence of both growth factors and serum but were also able to undergo unrestricted lineage-specific commitment and terminal differentiation under these conditions as well.52 A significant feature of Bcl-2 overexpression was prolongation of the G1 phase of the cell cycle.52 Importantly in this regard, in vitro, the duration of G1 in erythroid progenitor cells appeared to be erythropoietin dependent; low concentrations of erythropoietin were associated with G1 prolongation and initiation of differentiation while high concentrations were associated with G1 shortening and cell proliferation.53 Thus, Bcl-xl overexpression could explain the accelerated differentiation of polycythemia vera erythroid progenitor cells in vitro in the absence of erythropoietin in contrast to their normal counterparts, as well as their survival advantage in vivo where erythropoietin production is suppressed, since both conditions promote G1 arrest and terminal differentiation. Therefore, the excess of erythroid cells that defines this disorder is more likely a consequence of cell accumulation than cell proliferation. This type of behavior is also consistent with and explains the incremental nature of the erythrocytosis in polycythemia vera (Figure 2) since only a fraction (5%-25%) of the erythroid progenitor cell population exhibited this behavior and its expression appeared to be random.17 Whether resistance to apoptosis in the absence of growth factors is a feature of myelopoiesis or thrombopoiesis in this disorder remains to be determined. One caveat with respect to this mechanism is that Bcl-xl expression is normally up-regulated with terminal erythroid differentiation 54 and whether accelerated terminal erythroid differentiation in polycythemia vera was the cause of increased Bcl-xl expression or its consequence, and thus, whether another antiapoptotic mechanism might be involved, has not been established. Figure 2. Rate of rise of the

View larger version (15K): [in this window] [in a new window]

Figure 2. Rate of rise of the hematocrit level in a patient with polycythemia vera who sought treatment for the disease 9 years after the hematocrit level began to increase. Adapted from Conley 368 with permission of the publisher, The McGrawHill Companies.

IGF-1 Insight into the mechanism for the resistance of polycythemia vera erythroid progenitor cells to apoptosis was provided by the observation that in the absence of serum, polycythemia vera erythroid progenitor cells were not more sensitive to erythropoietin than their normal counterparts. Rather, they were more sensitive to the antiapoptotic growth factor IGF-1.22 Furthermore, IGF-1 receptors on polycythemia vera peripheral blood mononuclear cells were constitutively tyrosine phosphorylated in contrast to those of normal blood mononuclear cells and also more sensitive to IGF-1.55 The serum concentration of IGF-1 binding protein-1 was increased in polycythemia vera patients and this protein was capable of stimulating erythroid burst formation in vitro. 56 Importantly in this regard, it was recently demonstrated that cells expressing truncated erythropoietin receptors lacking their negative regulatory cytoplasmic domain and thought to be hypersensitive to erythropoietin36 were actually hyposensitive to the hormone in the absence of serum and hypersensitive to IGF-1.57 Thus, growth factor hypersensitivity in polycythemia vera could be a result of compensation for defective receptor-mediated signal transduction. The thrombopoietin receptor, Mpl Based on studies to date, the erythropoietin receptor cannot be implicated in such a process but the thrombopoietin receptor, Mpl, is a candidate. Mpl is expressed not only by megakaryocytes and platelets but also by pluripotent hematopoietic progenitor cells, 58 the survival of which is enhanced by the cognate ligand of Mpl, thrombopoietin.59 Thrombopoietin also acts synergistically with SCF and IL-3 to promote

the proliferation of pluripotent hematopoietic stem cells, 60 while impaired Mpl or thrombopoietin expression results in a reduction in the number of both multilineage and committed hematopoietic progenitor cells. 61 Thrombopoietin in conjunction with SCF promotes the production of neutrophils from CD34 + cells 62 and in conjunction with erythropoietin, the production of erythroid progenitor cells, 63 an effect that may be due to abrogation of apoptosis. 64 Thrombopoietin overexpression in mice caused granulocytosis, thrombocytosis, osteomyelofibrosis with extramedullary hematopoiesis, and death,65 while ectopic expression of Mpl caused fatal erythroblastosis. 66 Importantly, the retrovirus, MPLV, which encodes an Mpl gene truncated in its extracellular domain and fused with a viral envelope protein gene, induced a syndrome in mice that mimicked polycythemia vera,67 while hematopoietic progenitor cells infected with MPLV were growth factor-independent in vitro and capable of terminal differentiation in the absence of growth factors.68 Finally, Mpl expression and, therefore, its responsiveness to thrombopoietin in the megakaryocytes and platelets of polycythemia vera patients, were defective due to an as-yet-undefined impairment of its posttranslational glycosylation that became more profound with disease duration and extent. 69 These observations, taken together with the recent demonstration that removal of the Mpl distal extracellular cytokine receptor domain conferred growth factor-independent survival on hematopoietic cells expressing these truncated receptors,70 support the contentions that impaired hematopoietic growth factor receptor signaling has a fundamental role in the pathophysiology of polycythemia vera, that Mpl is a candidate receptor in this regard, and that polycythemia vera is a disorder of cell accumulation not cell proliferation.

The diagnosis of polycythemia vera: Osler's legacy; polycythemia vera is a clinical diagnosis
Diagnostic criteria William Osler was not the first to describe a patient with
Top Introduction The pathogenesis of... The diagnosis of polycythemia... Anecdote as paradigm: the...

Survival with polycythemia... polycythemia vera.3 He was, Phlebotomy and polycythemia... however, the first to emphasize that Thrombocytosis and polycythemia... The management of polycythemia... phenotypic mimicry could References confound the diagnostic process and to propose clinical criteria to distinguish polycythemia vera from other disorders causing erythrocytosis71 (Table 1). Remarkably, the Osler diagnostic criteria omit leukocytosis or thrombocytosis, an omission that may have diagnostic connotations as discussed below, but are otherwise similar to the major diagnostic criteria proposed by the Polycythemia Vera Study Group (PVSG) 6 decades later 72 (Table 1). These diagnostic criteria are as important for what they do not specify as for what they do. First, bone marrow examination is not part of the diagnostic criteria. This is appropriate because bone marrow abnormalities, such as an increase in megakaryocytes and cellular hyperplasia with a loss of the fat spaces, while characteristic, can never alone be diagnostic for polycythemia vera,73 and if the other major PVSG diagnostic criteria are met, bone marrow examination is unnecessary. Furthermore, while nonrandom cytogenetic abnormalities and myelofibrosis have diagnostic implications, neither has prognostic implications 74,75 and their frequency is too low to make bone marrow examination cost-effective. Even if bone marrow examination were diagnostic, that would still not abrogate the need for red cell mass and plasma volume determinations, tests that are justifiably cost-effective. Consequently, marrow examination is useful only when there is a change in the clinical course of the disease, for research purposes or for clinical trials. Yet, bone marrow aspiration and biopsy are frequently performed in the initial evaluation for polycythemia vera.7 This only confirms or generates an unexpressed fear of leukemia on the part of patients; a fear often validated by their physicians with respect to prognosis when in fact, with appropriate management, such an occurrence is only a remote possibility. Second, assays for erythropoietin and erythroid colony-forming cells are not part of the PVSG diagnostic criteria. While it can be argued that 30 years ago these tests were either insensitive or unavailable, it is equally easy to argue for the latter test that availability is still restricted clinically and that for both, specificity and sensitivity are unsatisfactory.

Table 1. The diagnosis of polycythemia vera

View this table: [in this window] [in a new window]

Serum erythropoietin The development of a sensitive and specific assay for circulating erythropoietin for the purpose of distinguishing autonomous from secondary erythrocytosis was long a holy grail of hematologists. Although we now have such an assay, it is an irony that due to the unique physiology of erythropoietin, measurement of the hormone in the circulation cannot be relied on to distinguish between autonomous and erythropoietin-driven erythrocytosis. This is because as the red cell mass expands, both improved tissue oxygenation and the associated increase in blood viscosity serve to depress erythropoietin production, 76 while the plasma residence of erythropoietin is simultaneously reduced through increased catabolism by the expanded erythroid progenitor cell pool. 77 The net result is that while the lowest erythropoietin levels occur in polycythemia vera14 (Figure 1), this is not absolute and a "normal" erythropoietin level is common in hypoxic erythrocytosis unless the hypoxia is extreme.78 Indeed, given the wide range of normal for serum erythropoietin (4 mU/mL-26 mU/mL), unless the premorbid serum erythropoietin level is known, a 6-fold elevation could occur without exceeding the normal range. Thus, while an elevated serum erythropoietin level suggests tissue hypoxia as a cause for erythrocytosis, a normal serum erythropoietin level does not exclude an hypoxic cause. Only an arterial oxygen saturation determination, as stipulated by the PVSG criteria, will suffice for this purpose. Erythroid progenitor cell assay Similarly, although erythropoietin-independent erythroid colony formation in vitro is characteristic of polycythemia vera15 and has been widely embraced as a diagnostic test for the disease, it cannot be recommended for this purpose. The reasons are many and cogent. Erythropoietin-independent erythroid colony formation is not specific for polycythemia vera. Although it is most obvious in this disorder, it can be seen in nonclonal causes of erythrocytosis79,80 and in healthy controls79,81 as well as in essential thrombocytosis.81-84 Furthermore,

endogenous erythroid colony formation has been absent in some patients who meet the PVSG criteria for polycythemia vera.85 Part of the problem may be methodologic since the greatest specificity and sensitivity has been observed when bone marrow was used as the source for erythroid progenitor cells as opposed to peripheral blood and when erythroid colony-forming units (CFU-Es) were analyzed as opposed to erythroid burst-forming units (BFU-Es). 86 The in vitro clonal assay for erythroid progenitor cells is also neither standardized nor widely available. For these reasons and because this assay does not establish clonality, it cannot be recommended as a routine clinical diagnostic test for polycythemia vera. PVSG minor criteria In an effort to improve diagnostic accuracy, particularly in the absence of splenomegaly, the PVSG added additional criteria such as the presence of leukocytosis and thrombocytosis. Approximately 60% of patients will not have both of these abnormalities initially4,87,88 nor will leukocyte alkaline phosphatase expression, serum vitamin B12, and unbound serum vitamin B12 binding capacity be uniformly elevated. 88,89 Impaired platelet Mpl expression A number of other phenotypic abnormalities of the red cells (eg, microcytic erythrocytosis,90 increased hemoglobin F synthesis18), white cells (eg, increased surface expression of IgG receptors,91 impaired responsiveness to chemotactants 92), and platelets (eg, reduced PGD 2 receptor expression, 93 impaired lipoxygenase generation 94,95) have been observed in polycythemia vera but none of these abnormalities are either specific for the disease or suitable clinically for diagnostic use. Recently, impaired expression of the thrombopoietin receptor, Mpl, by the platelets of polycythemia vera and idiopathic myelofibrosis patients was documented 96 and the severity of this defect correlated with the duration and extent of disease. 69 A similar abnormality was not present in secondary erythrocytosis or chronic myelogenous leukemia (CML) but was present in some patients with essential thrombocytosis.97 Interestingly, recently the development of polycythemia vera or idiopathic myelofibrosis was observed in 3 of 4 essential thrombocytosis patients with reduced platelet Mpl expression, 98 suggesting that the

abnormality could have prognostic significance in this disorder. Whether impaired platelet Mpl expression will prove clinically useful for distinguishing polycythemia vera from other types of erythrocytosis or to identify polycythemia vera in the absence of erythrocytosis remains to be established. However, the consistency with which impaired platelet and megakaryocyte Mpl expression was observed in polycythemia vera patients96,99 suggests that it may be useful diagnostically. PRV-1 expression Recently, overexpression of the mRNA of a novel member of the uPAR receptor superfamily, designated PRV-1, was identified in polycythemia vera granulocytes by subtractive hybridization. 89 This GPI-linked surface membrane receptor was detected only in normal granulocytes after exposure to granulocyte-colony-stimulating factor (G-CSF), was not expressed in the mononuclear cells from patients with secondary erythrocytosis, CML, or acute myelogenous leukemia (AML) and did not correlate with the expression of leukocyte alkaline phosphatase, another GPI-linked protein. 89 Interestingly, like impaired Mpl expression, PRV-1 expression has also been detected in certain patients with essential thrombocytosis who also demonstrated in vitro erythropoietin-independent colony formation. 100 Quantitation of PRV-1 mRNA expression may also prove useful diagnostically in distinguishing polycythemia vera from other disorders causing erythrocytosis. Clonality assays The most important omission from the PVSG diagnostic criteria for polycythemia vera was a requirement for the establishment of clonality. Unfortunately, however, in contrast to CML, there has been no clinically applicable clonal assay for polycythemia vera or its companion myeloproliferative disorders, idiopathic myelofibrosis and essential thrombocytosis. Nonrandom chromosome abnormalities are not uncommon in these disorders and in polycythemia vera the most frequent are trisomies of 1q, 8, 9 or 9p, del13q, del20q, or interstitial deletions of 13 or 20; occasionally multiple defects are present. 31,74,101,102 However, there is no consistent or unique cytogenetic abnormality associated with any of these disorders and at the time of diagnosis, using conventional cytogenetic techniques, less than

20% of polycythemia vera patients exhibit a cytogenetic abnormality and many patients never develop one. 74 In this regard, the use of interphase fluorescence in situ hybridization (FISH) may increase the diagnostic yield.32 However, bone marrow aspiration is still required for cytogenetic analysis unless there are numerous primitive cells in the circulation. In the absence of a specific and consistent cytogenetic marker, clonality assays in the chronic myeloproliferative disorders other than CML have been limited to genes on the X chromosome whose expression in women is subject to random inactivation. It was on this basis that the clonality of polycythemia vera was first established. 1 However, this type of clonal analysis is limited to women who are informative with respect to the expression of G-6PD isoenzymes or specific DNA polymorphisms. Expression of the former is restricted while the latter analysis is not informative in up to 30% of female patients103 and its utility is further limited by nonrandom, age-associated X-linked gene inactivation.104-106 Thus, although it has been clearly established as a general principle that polycythemia vera is a clonal disorder and represents the consequences of transformation of a multipotent hematopoietic progenitor cell, there is currently no way to establish clonality in the majority of patients considered to have the disease. While this is not an issue in patients exhibiting trilineage hematopoietic cell hyperplasia and extramedullary hematopoiesis, it is a critical issue in patients with erythrocytosis alone since in the absence of proof of clonality, it is difficult to justify the use of mutagenic drugs. Osler was well aware of the phenotypic mimicry that complicated the diagnosis of polycythemia vera71 and given the well-documented existence of unidentified and newly recognized nonclonal forms of erythrocytosis107,108 we would do well to follow his lead. Measurement of the red cell mass and plasma volume With respect to what the PVSG diagnostic criteria do stipulate, the most important is elevation of the red cell mass. Admittedly, this criterion does not establish clonality or even distinguish polycythemia vera from other disorders that cause erythrocytosis. However, it makes a vitally important point with respect to the evaluation of a high hematocrit level in general and polycythemia vera in particular that only direct

measurement of the red cell mass and plasma volume will suffice to distinguish absolute erythrocytosis from so-called spurious or relative erythrocytosis due to plasma volume contraction or red cell redistribution. 109-111 Indeed, it is not hyperbole to state that failure to appreciate this basic concept has been responsible for more diagnostic and therapeutic failures in patients with polycythemia vera than any other single factor. The reason appears to be a lack of understanding of the pathophysiology of the red mass and plasma volume in disorders causing erythrocytosis. Normally, the hematocrit or hemoglobin is maintained at a constant level that is characteristic for each individual but varies between individuals of the same sex by as much as 15% and between sexes by approximately 10%. As a corollary, erythropoietin production as represented by the serum erythropoietin level also remains constant. 112 With tissue hypoxia, regardless of cause, as the red cell mass increases there is usually a concomitant reduction in plasma volume. Given the other factors involved in plasma volume regulation as well as in its measurement, the magnitude of plasma volume reduction reported with hypoxic erythrocytosis due to right-to-left cardiac shunts,113 impaired pulmonary gas exchange, 114 carbon monoxide poisoning, 115 and low ambient oxygen tension 116 varies but the downward trend is unmistakable. It should not be surprising, therefore, that therapy with recombinant erythropoietin,117 androgenic steroids,118 and even blood transfusion 119 also leads to a reduction in plasma volume; the mechanisms involved are unknown but may in part be protective since increasing whole blood viscosity suppresses endogenous erythropoietin production. 76,120 By contrast, in polycythemia vera where erythropoiesis is autonomous and erythropoietin production is suppressed, as the red cell mass increases the plasma volume may be unchanged or increase 121 until the hematocrit level is more than 60%. 122 Unfortunately, the hematocrit level, whether directly determined by centrifugation or calculated from the mean corpuscular volume (MCV) and the red cell count, will not reflect these changes because even under normal circumstances, the distribution of red cells and plasma is not uniform throughout the circulatory system. 123-125 Rather, as demonstrated by independent determinations of the red cell mass and

plasma volume, the ratio of red cells to plasma is higher in the peripheral vessels, venous or arterial, than it is in the body as a whole (ie, whole body hematocrit derived from independent measurements of red cell mass and plasma volume/peripheral venous hematocrit = 0.92). 126,127 This is a consequence of both the slower flow of the peripherally displaced plasma compared with the axial red cells and plasma skimming in the smaller vessels. 123,125,128,129 With disease, changes occur in the plasma volume and red cell mass or in their distribution, particularly if there is splenomegaly121,130-132 that will not be evident by hematocrit level determination alone.109,133-136 Indeed, the assumption that the hematocrit accurately reflects the red cell mass or, stated differently, that the red cell mass:plasma volume ratio is constant in health and disease or even for all parts of the circulation, is simply incorrect and nowhere more so than when erythrocytosis is present. 114,127,134,136 Remarkably, although it was established in 1921123 and repeatedly confirmed125,126,137,138 that only by independently measuring the red cell mass (currently with 51chromium) and the plasma volume (with 125 I-albumin) could an accurate assessment of each as well as the total blood volume be obtained, there is still resistance to this standard of practice. The reasons for this are several. First, the range of normal for such measurements, not unlike the range of the hematocrit, is wide, which affects their sensitivity. Consequently, only values more than 2 standard deviations (25%) above the mean are considered abnormal. 139 Second, since adipose tissue has a low vascularity, red cell mass correlates better with lean body mass than body weight127 but, unfortunately, there is no simple method for clinically assessing lean body mass.111 Therefore, if body weight in mL/kg is used as standard, the red cell mass will be underestimated in the obese, 140 requiring correction factors based on weight.139 For these reasons and because of the need to use 2 radioisotopes, it has been variously advocated that the red cell mass be calculated from the plasma volume and the hematocrit 141 by a mathematical formula based on the regression of the red cell mass on the hematocrit, 142 or dispensed with altogether on the grounds that the diagnosis of polycythemia vera is usually clinically apparent on the basis of other findings. 143 None of these approaches are

either physiologically sound or clinically acceptable because they rely on assumptions about the red cell mass:plasma volume ratio derived from measurements in healthy individuals that are not valid in disease. 109,127 Simply stated, in disease, the red cell mass and plasma volume can vary independently of each other and it is no more possible to assess the red cell mass from the hematocrit than it is to determine total body sodium from the serum sodium concentration. Splenomegaly, of course, just compounds the problem. 130-132,144 Stated differently, it is the author's opinion that whenever the diagnosis of polycythemia vera is considered, due to the potential of plasma volume expansion, a "normal" hematocrit value can never be considered normal and an independent determination of both the red cell mass and plasma volume by isotope dilution is mandatory for diagnostic and therapeutic purposes. Examples of the usefulness of red cell mass and plasma volume measurements in the evaluation of the cause of a high hematocrit level are shown in Table 2. Table 2. Examples of the diagnostic value of View this table: red cell mass (RCM) and plasma volume [in this window] (PV) determinations [in a new window]

Anecdote as paradigm: the natural history of polycythemia vera has not yet been defined
Top The description of the natural Introduction history of polycythemia vera in The pathogenesis of... current hematology textbooks The diagnosis of polycythemia... Anecdote as paradigm: the... disguises the fact that little more is Survival with polycythemia... known today about its clinical Phlebotomy and polycythemia... course than was known 80 years Thrombocytosis and polycythemia... The management of polycythemia... ago. Attempts to define the natural References history of polycythemia vera then as now have been frustrated not only by the low incidence of the disorder but also its chronic nature which precludes most physicians from seeing more than a few of these patients or even following them for a sufficient duration to encounter the full scope of the disease. These

factors coupled with an initial lack of appreciation of the effect of radiation or chemotherapy on bone marrow function led to the acceptance of anecdotal case studies as representative of the natural history of polycythemia vera. The natural history hypothesis In 1954, based on such anecdotal reports, a hypothetical description of the natural history of polycythemia vera was proposed by Wasserman according to which the disease evolved through a series of clinical stages beginning with an asymptomatic phase and proceeding through erythrocytotic, compensated or inactive, and spent or postpolycythemic myeloid metaplasia phases before terminating in acute leukemia if death from another cause did not intervene first.145 Given the similarity of this proposed natural history to that of CML, it is not surprising that without either testing or debate, the status of dogma was promptly conferred on this hypothetical description, and for the past 46 years it has been reiterated unchanged in greater or lesser detail in virtually every major hematology textbook when in fact the clinical data from which it was derived fail to meet the lowest standard of evidence-based medicine. Indeed, the basis for this concept of the natural history of polycythemia vera was a 1938 publication by Rosenthal and Bassen describing 13 patients from a series of 75 who were thought to be representative of the various hematologic manifestations of the disease. 146 Of the 13 patients. 2 were anemic and thereby thought to manifest the so-called "spent" phase of the disorder, a concept first proposed by Minot and Buckman. 147 Both, however, had previously been treated with radiation therapy. Dameshek had earlier proposed a similar natural history scheme148 but qualified his proposal as follows: "it is difficult to state what the `normal' course of the disease would be without the various therapeutic methods which undoubtedly influence it." Unfortunately, this caveat was disregarded and only rarely have polycythemia vera patients been followed long enough without exposure to therapeutic interventions such as radiation or 32P that significantly alter bone marrow function for any meaningful appreciation of the natural history of the disorder to be obtained. When this has been achieved, a different picture of the disease

emerges. 149,150 Additionally, it is not widely appreciated that the disease may have different manifestations depending on the age at onset and the patient's sex. 151 Finally, adding to the confusion has been the uncritical acceptance or misuse of terms such as "spent phase" and "postpolycythemic myeloid metaplasia" together with the assumption that the various chronic myeloproliferative disorders are interrelated152 when in fact proof is lacking that they are.153 The spent phase of polycythemia vera While it has been clearly established that polycythemia vera can be complicated by anemia, myelofibrosis, and myeloid metaplasia, the frequency with which these complications occur and their clinical significance in the absence of cytotoxic therapy has rarely been ascertained prospectively. For example, the development of anemia due to bone marrow exhaustion has been considered an inevitable event in the natural history of polycythemia vera and possibly a forerunner of leukemia.145,154 As mentioned above, it was in this context that the term "spent phase" was initially used. 147 However, in a large series of polycythemia vera patients managed without radiation therapy, anemia was most often due to chemotherapy, hemorrhage, deficiency of iron, folic acid or vitamin B12, or another disease and not to intrinsic marrow failure.149 Importantly, the role of iron deficiency as a cause for anemia was not recognized in early descriptions of the disease, 147 nor was it appreciated that the plasma volume expansion associated with splenomegaly could mask the true red cell mass. Furthermore, in some patients, the "spent phase" proved to be reversible with therapy.150 When these facts, together with ferrokinetic studies in patients with advanced disease 155 are taken into account, it is clear that that there is not necessarily an irreversible exhaustion of erythropoiesis with disease progression or duration and that while the frequency with which refractory anemia is a direct consequence of polycythemia vera remains to be established, from the available data, it appears to be uncommon.156,157 More important than the so-called spent phase is the peculiar wasting syndrome that can develop late in the course of polycythemia vera in which intractable weight loss is associated with extramedullary hematopoiesis and substantial elevation of the white cell and platelet counts.

Finally, the term "spent phase" as used today also appears to mean different things to different authors. Initially and still employed to denote the progression of polycythemia vera to a state of bone marrow failure and possibly a prelude to leukemia145,146 it has also been used to describe a phase of polycythemia vera with splenomegaly without either myelofibrosis or myeloid metaplasia in which erythrocytosis continues unabated with its extent masked by plasma volume expansion.136 As indicated above, the former use of the term has never been authenticated in a scientifically acceptable fashion and the latter use, of course, is actually contradictory since in the type of patients described, bone marrow function was actually robust.155,158 Furthermore, such patients have also been described by others as being in the "stationary phase" of the disease, 148 a designation that is equally improbable since no evidence has been provided that disease activity has changed. All of this only serves to illustrate the confusion that results when anecdotal experiences are uncritically elevated to the status of paradigm and medical jargon is substituted for medical judgment. In a disease such as polycythemia vera, anecdotal case reports are invaluable for defining what is possible but only prospective longitudinal studies of well-defined patient cohorts can establish what is probable. Myeloid metaplasia This conclusion also applies to 2 other complications of polycythemia vera, myeloid metaplasia and myelofibrosis. Since splenomegaly in polycythemia vera is initially due to red cell congestion, 13,159-161 without a tissue biopsy, the assumption that splenic enlargement represents extramedullary hematopoiesis could be erroneous. 133,162 It is probably for this reason that estimates of the frequency of myeloid metaplasia, based on the presence of immature myeloid and erythroid cells in the circulation or organomegaly, have varied from 7% to 14%. 75,145,157,163 Furthermore, the widely used term "postpolycythemic myeloid metaplasia"164 is more than imprecise; it is an oxymoron since it implies that myeloid metaplasia is a terminal complication or conversion of polycythemia vera to another disorder rather than being an integral component of the disease itself165 that may not shorten survival.75,166,167 It also implies that bone marrow activity is impaired when in fact, in the absence of radiation or chemotherapy, there is no

correlation between the extent of extramedullary hematopoiesis and bone marrow hematopoietic activity in polycythemia vera. 168 As originally used, "postpolycythemic myeloid metaplasia" was a synonym for the spent phase of polycythemia vera in which the predominant features were myeloid metaplasia, splenomegaly, myelofibrosis, and anemia. 164 However, as indicated above with respect to anemia, there have been few attempts to analyze the influence of radiation or chemotherapy on the development of "postpolycythemic myeloid metaplasia" but when this has been done, the majority of patients fitting this description have been exposed to agents toxic to the bone marrow.163,164,169 Thus, a century after the description of polycythemia vera, judgment must remain suspended as to the frequency with which bone marrow failure is a terminal feature of this disease in the absence of an exogenous cause but published data suggest that it is not high. 157 Myelofibrosis Given the above, it should not be surprising, therefore, that substantial misconceptions also exist with respect to significance of myelofibrosis in polycythemia vera. This is because the mechanisms for myelofibrosis are poorly understood 170-172 and the means for quantitating it imprecise due to the patchy nature of the process.168,173-175 Furthermore, with respect to diagnosis, it has generally been assumed that polycythemia vera and idiopathic myelofibrosis are closely related disorders,152 although apart from phenotypic similarities, this assumption has never been substantiated scientifically. Indeed, some investigators have considered the development of myeloid metaplasia and myelofibrosis in polycythemia vera as indicating the onset of a "transitional myeloproliferative disorder"135 rather than part of the natural history of the disease, while others have considered erythrocytosis to be a complication of idiopathic myelofibrosis.134 The development of myelofibrosis per se in the setting of polycythemia vera has also been considered to have adverse prognostic implications, 176 another erroneous assumption.75,150,156,174,177 Because there is no widely accepted standard for the quantitation of marrow reticulin 158 nor a universally acknowledged definition for the

term "myelofibrosis" outside the setting of the disease, idiopathic myelofibrosis,178 it is difficult to obtain a precise frequency for its occurrence in polycythemia vera as well as the impact of therapy on this. Within the limitations of these data, it appears that increased marrow reticulin is part of the natural history of the disease, presumably reflecting in part the increase in marrow cellularity158,179 and possibly disease duration. 180 However, an increase in marrow reticulin, or even osteosclerosis, is certainly not synonymous with a "spent" phase 75,134,135,155,158,181-183 and can be modified to a certain extent by therapy,75 particularly with busulfan. 182,184 Spontaneous regression of myelofibrosis has also been observed,168,175,182,185,186 although the patchy nature of the process makes this observation as difficult to substantiate as the contention that myelofibrosis is a progressive and destructive process.173-175,187 If studies of idiopathic myelofibrosis patients can be used as a guide, myelofibrosis and osteosclerosis are not usually progressive processes. 168,174,188 There does, however, appear to be a higher incidence of "myelofibrosis" in polycythemia vera patients exposed to either radiation or chemotherapy than those treated by phlebotomy alone, 8.4% 156,163,164,173,189 versus 4.5%, 149,156,163 but there is not absolute agreement on this point.75,176 As a corollary, in studies of idiopathic myelofibrosis, polycythemia vera patients comprised 16% (range, 7%38%) of the patients and most had been treated with radiation or chemotherapy.173,175,177,190-193 To the extent that it has been evaluated, marrow reticulin was increased in 8% to 15% of polycythemia vera patients at the time of diagnosis, 73,181,194,195 a finding that appeared to have no prognostic significance. 75,150,167 This is in contrast to development of myelofibrosis in CML, which is generally associated with disease acceleration. 196 Taking everything together, while it is clear that the hematologic manifestations of polycythemia vera include myeloid metaplasia and myelofibrosis, it is not yet established that these processes indicate terminal bone marrow failure or that marrow failure is an inevitable consequence of the disease in the absence of cytotoxic therapy. Certainly, given the limitations of the data upon which the current concept of the natural history of polycythemia vera is based, it is time to abandon uncritical and unphysiologic terms such as "stationary," "spent," "transitional," and "postpolycythemic myeloid metaplasia" in

favor of descriptions based on quantitative, prospective, and biologically sound observations. Acute leukemia: relationship to therapy The relationship between polycythemia vera and acute leukemia also requires clarification because it is central to the management of polycythemia vera. In 1950, Schwartz and Ehrlich reviewed the published evidence that acute leukemia was a feature of polycythemia vera in the absence of exposure to mutagenic therapy.197 Of 83 published cases, only 30 had unequivocal evidence of polycythemia vera preceding the development of acute leukemia and 25 of these patients had been irradiated. Of the remaining 5 patients, data supporting the absence of radiation exposure were available for only one. Since the criteria employed by Schwartz and Ehrlich for the diagnosis of polycythemia vera and the diagnosis of acute leukemia were stringent, it is ironic that in the one case of polycythemia vera that they accepted as spontaneously developing acute leukemia, the diagnosis was not histologically confirmed.146 They also emphasized the association of the newly introduced 32P therapy with acute leukemia in polycythemia vera patients and correctly predicted that this complication would increase in frequency. By contrast, the advocates of 32P therapy thought that the development of acute leukemia was an inevitable consequence of extended patient survival.133,198 Modan and Lilienfeld's landmark 1965 paper unequivocally demonstrated that the leukemogenic effect of irradiation or 32P was not a consequence of prolonged survival,163 but the impact of their observations was blunted by the report of Halnan and Russell in which the incidence of acute leukemia in 32P-treated polycythemia vera patients was negligible.199 Any doubt about this issue, however, was eliminated by the PVSG-01 trial which established that therapy with either 32P or the alkylating agent, chlorambucil, resulted in an incidence of acute leukemia far exceeding that observed with phlebotomy alone without prolonging survival.200 The apparent conflict between the Modan and Lilienfeld data and that of Halnan and Russell was in part due to study design, since the mean time of onset of 32P-induced acute leukemia is approximately 8.5 years201 while most of Halnan and Russell's patients were followed for only 5 years, and in part to

differences in radiation dose. Parenthetically, this episode serves to remind us that the absence of evidence is not proof of its absence. Polycythemia vera has the dubious distinction of being the first hematologic malignancy and only the third disorder temporally ankylosing spondylitis 202 and thymic enlargement 203 being the other 2 in which an association between acute leukemia and therapeutic irradiation was identified. 197 Unfortunately, acceptance of the leukemogenicity of irradiation in polycythemia vera was delayed by the belief that leukemia was an inevitable feature of the disease. 145,154,204 As a consequence, practitioners in this area were denied an essential paradigm to guide their therapy until similar observations had been well established for other hematologic 205 and nonhematologic neoplasms.206 Importantly, from a biologic perspective, the leukemogenic effect of irradiation or alkylating agents in polycythemia vera was neither qualitatively nor quantitatively different from that observed for other neoplasms treated in the same fashion with respect to drug or radiation exposure, latency, type of leukemia, cytogenetic abnormalities, and response to treatment. 180,207,208 Although data have been presented suggesting that myeloid metaplasia and myelofibrosis predispose to acute leukemia in polycythemia vera,145,193,209 this contention remains controversial since the number of patients involved was small and the observations were not confirmed in other studies. 163,167,180 Furthermore, therapy-induced acute leukemia has also been observed in patients with secondary erythrocytosis mistakenly treated with chemotherapy or radiation.163,210,211 These considerations are not trivial since they speak to the larger underlying issue of the spontaneous development of acute leukemia in polycythemia vera. Spontaneous acute leukemia: Richter syndrome revisited In contrast to the well-established body of data on treatment-induced acute leukemia in polycythemia vera,163,180,197,200,207,212-214 few data exist other than anecdotal case reports with respect to the spontaneous occurrence of acute leukemia. As mentioned above, up to 1950, Schwartz and Ehrlich accepted as valid only one published report describing such an event.197 In the same year, Dameshek reported that one of his 50 patients and 2 of 100 Mayo Clinic patients treated only by

phlebotomy had developed acute leukemia.148 Since then there have been 12 individually published case reports 215-217 and an additional 11 patients identified by questionnaire 215 in whom acute leukemia complicated polycythemia vera in the absence of irradiation or chemotherapy, while in 4 published series comprising 505 patients, 3 cases of spontaneous acute leukemia were observed.149,156,163,218 Demographically, these patients are of interest because 90% were men with a mean age of 60.5 years, in contrast to those developing acute leukemia following alkylating agent therapy, of whom 54% were men with a mean age of 52.5 years. The interval for the former group between the onset of polycythemia vera and acute leukemia was 4.8 years (range, 1-13 years) and in the chemotherapy-treated group 6.7 years (range, 1-20 years), but these latter data are not comparable because the time of initiation of alkylating agent therapy relative to the onset of the polycythemia vera was not defined. It is also of interest that 3 of the 10 patients in the spontaneous leukemia group for whom the information was available had undergone splenectomy 2 to 8 years before the onset of the leukemia.193,219 Finally, in contrast to the chemotherapy-treated patients, patients developing spontaneous acute leukemia could still have concomitant erythrocytosis and only partial bone marrow transformation at the time that the leukemia was recognized. 220 Second cancers occur more often than can be explained by chance in patients already afflicted by a malignancy221 but with the exception of exposure to radiation, radiomimetic drugs, or a combination of these, the mechanisms involved are undefined. With respect to the development of secondary acute leukemia, age, disease stage, type of cancer,221 and immunologic status including the postsplenectomy state 222-225 have all been considered to have a role. In some instances, the development of myelodysplasia or acute leukemia could even be considered a paraneoplastic syndrome 226,227 since there is precedent for the cytokinedriven development of acute leukemia.228 With respect to polycythemia vera, given the increasing incidence of acute leukemia with age, 5 the mean age of polycythemia vera patients, and the restoration of the polycythemic state with successful remission induction therapy,220,229,230 the possibility of a chance occurrence cannot be excluded particularly with the simultaneous presence of both

disorders.229 At the same time, given the evidence of clonal evolution or succession in polycythemia vera,74 the possibility of leukemia arising from the malignant clone is also likely. The role of splenectomy is intriguing since this has been implicated in the evolution of acute leukemia in idiopathic myelofibrosis223 although the observation remains controversial.231 Importantly, the polycythemia vera patients with spontaneous acute leukemia described to date differ from those with treatment-induced acute leukemia not only by their male predominance but also by their age at onset and the short interval between the diagnosis of polycythemia vera and the development of acute leukemia, thereby excluding prolonged survival, myeloid metaplasia, or myelofibrosis as antecedent factors as claimed.209,218 In fact, the situation is similar in many respects to Richter syndrome, in which chronic lymphocytic leukemia is complicated by either the development of a diffuse large cell lymphoma or transformation to prolymphocytic leukemia.232 These uncommon events can occur in untreated patients without regard to disease duration and may arise from either the original malignant clone or one immunologically distinct. 233 However, regardless of mechanism, the important point is that the spontaneous development of acute leukemia in polycythemia vera is uncommon and certainly not inevitable, and our patients deserve to know this.

Survival with polycythemia vera: hematology's second amendment privilege
Top Probably no myth has been more Introduction pernicious with respect to the well The pathogenesis of... being of polycythemia vera The diagnosis of polycythemia... Anecdote as paradigm: the... patients than the myth of survival Survival with polycythemia... which exists in 2 versions. It is Phlebotomy and polycythemia... difficult to understand how this Thrombocytosis and polycythemia... myth attained credibility since The management of polycythemia... References there were both anecdotal reports 185,234,235 and observational series 146,147,149,236 that firmly established the prolonged survival of polycythemia vera patients in an era when the mainstays of

therapy were phlebotomy, phenylhydrazine, and sporadic irradiation. Unfortunately, these observations were ignored in favor of the first version of the myth which arose from the assumption that leukemia was an inevitable feature of polycythemia vera.198 This position was stated most emphatically by Osgood,237 "...for any treatment the benefits to be obtained must be weighed against the risks incurred. Most patients would rather die at an advanced age with some risk of leukemia than at an earlier age from some other cause." However, no patients appear to have been polled about this contention but it would be more realistic to conclude that most would rather die at an advanced age with no risk of leukemia. The second version derived from an early attempt to study survival in polycythemia vera in a systematic fashion. In 1962, Chievitz and Thiede reviewed the causes of death in 250 Danish polycythemia vera patients. Among their conclusions were the following: "Out of the untreated patients, 50% had died 18 months after the onset of the first symptom or sign, and out of patients treated with venesection half had died 3 1/2 years after this juncture. Out of patients treated by X-rays half were alive 12 1/2 years after the first sign." 156 This article was one of the first to report survival data and has been the rationale for the implementation of various treatments for polycythemia vera without provision for the inclusion of the appropriate phlebotomy control group. 238 And this was true even though 12 years previously, another Danish physician, Videbaek, reporting on a series of 125 patients, noted a 50% survival of 4.5 years for men and 8.5 years for women treated with phlebotomy or irradiation but not 32P.239 Indeed, Videbaek came to the conclusion that "...a large proportion of the high mortality which is known to attend polycythemia vera is not due to inadequacy of the therapeutic measures, but rather to the fact that the patients are not followed up as they should be," a point ignored not only by Chievitz and Thiede but also by many in the hematology community.201,240-242 The differences between the experience of Videbaek and that of Chievitz and Thiede can be explained in part by the fact that more than twice as many of the patients in the latter series were older than 65 years and age of onset appears to influence survival.215 At the same time, Videbaek's patients undoubtedly had less access to medical care, which was also

likely to have been of a lower standard, making the differences in survival even more striking. Furthermore, as stated previously, the literature contains sufficient other support for the contention that the clinical course of polycythemia vera, without treatment or treatment mainly by phlebotomy, was not as dismal as described above. 149,150 Therefore, it is difficult to explain the universally uncritical acceptance of Chievitz and Thiede's conclusions except on the grounds that they either suited the prejudice of those who were enamored of particular therapies such as 32P204,237 or provided hematologists with the same type of "constitutional privilege" with respect to the treatment of polycythemia vera200,201,243,244 that is invoked by those American citizens who support the right to bear arms without restriction. Indeed, even today, there are advocates of 32P therapy,201,245 although it has been widely appreciated for 50 years that this agent was least effective against the most troublesome feature of polycythemia vera, extramedullary hematopoiesis.167,189,246 Central to the myth of survival is the assumption that polycythemia vera is a monolithic disease when in fact it is not 122,146,246,247 and while no one would advocate withholding treatment once the diagnosis was established, it is important to emphasize that the disease can develop gradually and be substantially advanced before it becomes clinically problematic (Figure 2). Presumably, this is a consequence not only of the slow rate of hematopoietic cell accumulation but also the concomitant compensatory expansion of the plasma volume. The occurrence of a preclinical or asymptomatic phase was first documented by Rosenthal and Bassen, 146 confirmed by Dameshek,148 and calculated to be between 17 and 80 months by Swolin et al based on the rate of accrual of cytogenetic abnormalities. 74 The Gruppo Italiano Studio Policitemia documented a significant incidence of thrombosis more than 2 years before the diagnosis of polycythemia vera,244 as did the PVSG,248 and in another study, 11 of 13 patients with an intraabdominal venous thrombosis had an elevated hematocrit level for 6 or more months before onset of thrombosis, 249 also supporting a significant latent period even in symptomatic patients. Finally, Rozman et al250 and others 251 have presented data suggesting that the life expectancy of polycythemia vera patients in the modern era was not greatly different from normal. Since both retrospective163 and prospective controlled

clinical trials have established that radiation or chemotherapy did not prolong life more than phlebotomy, 200 and that the course of polycythemia vera is generally indolent, its management should be in keeping with its tempo and not with what we should acknowledge to be historical inaccuracies.

Phlebotomy and polycythemia vera: women are not small men
Thrombosis and hemorrhage in polycythemia vera
Top Introduction The pathogenesis of... The diagnosis of polycythemia... Anecdote as paradigm: the... Survival with polycythemia... Phlebotomy and polycythemia... Thrombocytosis and polycythemia... The management of polycythemia... References

Erythrocytosis not only distinguishes polycythemia vera from its companion myeloproliferative disorders but is also responsible for its most frequent and serious complications. Published data indicate that thrombosis was the presenting feature in 12% to 49% of patients,133,149,156,194,239,244,252,253 occurred in up to 40% during the course of the illness,194 and was the cause of death in 20% to 40%. 145,149,156,239,244,254 Furthermore, in 2 studies, 14% to 15% of patients had a history of a thrombotic event at least 2 years before diagnosis. 244,248 In general, the central nervous system was the most frequent site of thrombosis, 156,244,253,255 arterial thrombosis was more common than venous 156,244,253-255 and the latter was characteristically cerebral or intraabdominal and more frequent in women, 151,194,241 possibly in keeping with their higher incidence of splenomegaly at presentation. 239 Indeed, polycythemia vera was the most common cause of hepatic vein thrombosis in the Western hemisphere.256 Finally, although not as frequent as thrombosis, hemorrhage in polycythemia vera was generally considered to be a consequence of vascular stasis and thrombocytosis133,149,257 and like thrombotic events, primarily involved the central nervous system and the gastrointestinal tract, was a presenting manifestation in 6% to 58% of patients149,156,194,239 and fatal in up to 30.149,156,239,254 Whole blood viscosity

The mechanisms involved in the hypercoagulable state that characterizes polycythemia vera are currently still under scrutiny258 even though they were apparent to the first clinicians to study the disease. The hematocrit is the principal determinant of blood viscosity259-261 and nowhere is this more evident than in polycythemia vera. Perhaps the most cogent observation in this regard was made by Weber in 1908, "In every case examined after death the distention of the visceral vessels has been very striking, the mesenteric vessels presenting sometimes the appearance of having been forcibly injected for purposes of anatomical demonstration." 262 Brown and Giffin added to that description in 1923 with their study of nail-fold capillaries, which were elongated and engorged to capacity due to the formation of red cell aggregates, leading to diminution of blood flow that was most marked in the venous limb. 263 Since cardiac output was either normal or increased in polycythemia vera patients due to an increased stroke volume,264,265 the diminution in capillary flow appeared to represent the influence of both peripheral vasodilatation and increased blood viscosity. In this regard, it needs to be emphasized that major vessel venous thrombosis in polycythemia vera most likely represents the end stage of a process beginning in very small vessels. 266 These observations are also compatible with the preponderance of thrombotic events in the brain and the abdomen. In the former, an increase in hematocrit was associated with a decrease in blood flow, 267-269 while the latter appears to be particularly vulnerable to disorders conducive to stasis or endothelial damage such as sickle cell anemia or paroxysmal nocturnal hemoglobinuria. Although it has been argued that the decrease in cerebral blood flow associated with a high hematocrit level is a physiologic response to increased oxygenation not increased viscosity,270 the data upon which this contention are based either actually support the latter process270,271 or fail to substantiate the former since the subjects studied were actually not sufficiently hyperviscous. 272,273 On the contrary, there are physiologically sound data indicating that cerebral blood flow like blood flow elsewhere274 declines independently of oxygen transport when blood viscosity increases.275 Blood viscosity is an exponential function of the hematocrit 259 and red cell aggregation increases at high hematocrit levels, 276 creating the

potential for vascular stasis if red cell production is left checked. While no other mechanism for thrombosis need be invoked in this circumstance, other mechanisms could contribute. Thus, increasing the hematocrit at flow rates found in the arterial circulation enhanced platelet-vessel wall interactions277 and this mechanism could be involved in the high incidence of arterial thromboses without requiring an elevation in platelet count.255 Additionally, a high hematocrit level has also been found to interfere with the vasodilatory effects of nitrous oxide278 which could account for the hypertension associated with polycythemia vera133,149,239,279 as well as its thrombotic tendency. Leukocytes can impede red cell migration in capillaries,280 interact with platelets at the vessel wall,281 and appear to be activated in polycythemia vera,282,283 but their role in the thrombotic process remains undefined because polycythemia vera patients treated with chemotherapy did not have a greatly diminished risk of thrombotic events.200 Finally, although impairment of the fibrinolytic system 284 and platelet activation 285 have been observed in polycythemia vera patients, such defects were not limited to this myeloproliferative disorder. For example, spontaneous platelet aggregation was most marked in patients with idiopathic myelofibrosis286 who were more prone to hemorrhage than thrombosis. 287 Finally, there is no evidence that other coagulation defects predisposing to hypercoagulability are more prevalent in polycythemia vera patients than in the general population, although they are certainly not immune to them.288,289 Phlebotomy therapy: pros and cons Not only is there compelling evidence that increased blood viscosity due to an elevated red cell mass is the principal basis for the hypercoagulable state in polycythemia vera, there is equally strong evidence that phlebotomy, a venerable practice that was well known in the Hippocratic era, is the most effective remedy. Unfortunately, it is both an irony and a tragedy that this is one Hippocratic principle that many hematologists have been reluctant to embrace wholeheartedly. The reasons are many but none are clinically tenable or physiologically sound. First, although phlebotomy was recognized by early clinicians as an effective method of bringing symptomatic relief to polycythemia vera patients, the adequate or consistent application of phlebotomy was deterred by the concern that

it would stimulate new blood formation. Thus, in 1928, an authoritative review of the disease stated "One must conclude that while venesection is an important and useful in relief in emergency in the treatment of these patients, it cannot be looked upon in any other light than as a further, and therefore undesirable stimulant to new blood formation."159 This contention, reaffirmed more than once in modern times in the absence of any data,87,145,148,290 is, of course, erroneous, since bone marrow function in polycythemia vera, as in the other myeloproliferative disorders, is autonomous and erythropoiesis can neither be suppressed by hyperoxia10,291 nor substantially stimulated by hypoxia292 or phlebotomy, 12,13,293 and this appears to be true for thrombopoiesis as well in the absence of anemia. 150,182,293-295 Second, it has been contended that phlebotomy provokes hypercoagulability. As stated by Osgood, "The major risks from phlebotomy are that it sets in motion all the clotting mechanisms plus suddenly reducing blood volume and possibly slowing the blood current and results in increased risk of thromboses and iron deficiency." 238 All aspects of this contention are indefensible. First, to the extent that any form of erythrocytosis provokes a hemorrhagic diathesis, phlebotomy restores coagulant activity toward normal by reducing blood viscosity296,297 and thereby improving blood flow, platelet function, 298,299 and the balance between coagulation factor concentration and red cell number, and this is as true in polycythemia vera133,300 as in the erythrocytosis of cyanotic congenital heart disease. 301 Second, in contrast to 32P therapy, venesection actually expands the plasma volume and thus results in a greater reduction in blood viscosity for any reduction in red cell mass than the former297 (Table 3). Paradoxically, this effect of venesection is also observed in pseudoerythrocytosis in which the plasma volume is reduced,302 an effect not always recognized. 110 Moreover, in addition to a direct reduction in total blood volume, plasma volume expansion is another relatively immediate effect, 303 making phlebotomy at once both corrective and protective. Finally, the effectiveness of venesection in relieving symptoms due to an elevated red cell mass has been repeatedly documented in patients with secondary forms of erythrocytosis.304-307 Table 3. Effect of 32P therapy or phlebotomy

View this table:

View this table: on the plasma volume and systemic vascular [in this window] resistance in polycythemia vera [in a new window]

Iron deficiency and whole blood viscosity Concerns over the adverse effects of phlebotomy-induced iron deficiency relate to both its side effects and the potential for increased blood viscosity.308,309 The former concern was addressed by exercise studies of chronically iron-deficient polycythemia vera patients in whom no impairment of aerobic capacity was detected, 310 nor were functional signs of iron deficiency observed other than the gustatory perversion pica.311 Iron deficiency-related hyperviscosity is a test tube artifact 308,309 that also has no physiologic basis.312,313 Although irondeficient red cell membranes may be less deformable than normal, 314 this abnormality is apparently offset by their reduced size and internal viscosity since their hemoglobin content is also reduced.315 Thus, at comparable hematocrit levels, iron-deficient blood was not more viscous than normal. 312,313 Furthermore, red cell-platelet interactions are influenced by red cell diameter and such interactions are reduced with small red cells. 315 Finally, a state of chronic iron deficiency that limits erythropoiesis is actually the ultimate goal of phlebotomy therapy in polycythemia vera, a goal that is unfortunately frequently not achieved judging from published results.156,200,239,244 Phlebotomy and myelofibrosis A more serious claim has been that the use of phlebotomy therapy alone in polycythemia vera results in a high incidence of myelofibrosis,316 a claim that is difficult to understand except as population specific since it is contrary to most published experience. For example, in a series of 207 patients followed for more than 10 years, only 4 patients treated solely by phlebotomy developed myelofibrosis,149 while in another series of 250 patients, none of the patients treated solely by phlebotomy developed myelofibrosis.156 Indeed, this experience has been the rule148,156,163 rather than the exception. As a corollary, the low incidence of polycythemia vera patients recorded in a published series of myelofibrosis patients173,175,190,192 as well as the high incidence of myelofibrosis observed in patients treated with hydroxyurea169 suggest

that this complication is neither frequent nor limited to patients exposed only to phlebotomy. Furthermore, since myelofibrosis can be a presenting manifestation of polycythemia vera73,317 and also occurs in patients exposed to 32P163,189,318 and x-ray therapy,156,163,234 there are no grounds to implicate venesection as a specific causal factor. An additional difficulty in this regard, as discussed above, is the definition of myelofibrosis; a dry tap or increased reticulin is not sufficient for this purpose.158,179 Finally, implicit in this contention is the notion that myelofibrosis is deleterious in polycythemia vera, when in fact it is perfectly compatible with normal bone marrow function, 134,155,181,183 is a reversible process,168,175,184-186 and has not been shown to impact adversely on survival.150,174,177 Indeed, failure to recognize polycythemia vera presenting as myelofibrosis is potentially more deleterious than the development of myelofibrosis during the course of the disease. Phlebotomy and thrombosis The most serious and damaging criticism of phlebotomy therapy in polycythemia vera is that it was associated with an excess of thrombotic events compared with other treatments.200 Unfortunately, the data upon which this criticism is based were the consequence of a complete misunderstanding of the pathophysiology of erythrocytosis in polycythemia vera. In contrast to other forms of erythrocytosis in which expansion of the red cell mass is typically accompanied by a reduction in plasma volume, expansion of the plasma volume is common in polycythemia vera.110,132 That this was not initially appreciated was presumably due to the practice of measuring only the red cell mass.319 Plasma volume expansion is associated with a concomitant reduction in peripheral vascular resistance and an increased cardiac stroke volume for its accommodation. As a consequence, although peripheral vascular resistance eventually increases, it does so more slowly than when erythrocytosis occurs in a normovolemic setting and systemic oxygen transport is actually increased at any given hematocrit level. 320 However, because of the plasma volume expansion, the hematocrit is no longer an accurate indicator of the red cell mass in polycythemia vera patients and this is particularly true when splenomegaly is present. 130-132 Therefore, it is not surprising that PVSG data indicated that

approximately 15% of patients with a hematocrit level of 50% and up to 40% with hematocrit levels of up to 55% had an elevated red cell mass88; similar observations have been made by others. 321 More importantly, not only is cerebral blood flow impaired in polycythemia vera patients when the hematocrit level is more than 45%, 267 but the incidence of thrombotic events shows a linear increase above the same hematocrit level. 322 Thus, hematocrit values that are apparently within the normal range cannot be considered as safe in polycythemia vera patients and it is this syndrome of masked or inapparent erythrocytosis132 due to plasma volume expansion that is not only responsible for what has been termed a latent,323 "prethrombotic,"244 or "forme fruste"324 myeloproliferative disorder but also the increased incidence of thrombotic events in such patients. Since even under normal circumstances, the hematocrit level in most organs with the exception of the spleen is much lower than the venous hematocrit level, 124 it is clear that the situation in polycythemia vera is actually more serious than it appears and that the so-called "prethrombotic state" of polycythemia vera merely reflects inadequate reduction of the red cell mass. The physiology of red cell mass expansion in polycythemia vera appeared to have been disregarded in the defining PVSG protocol-01, in which the phlebotomy treatment threshold was initially set at 50%, 72 even though as indicated above, a minimum of 15% of male patients would be undertreated at this hematocrit level, as would 100% of women, since no woman normally has a hematocrit level of 50%. Unfortunately, even when the hematocrit threshold for phlebotomy was subsequently lowered to 45%, 248 women patients were still at risk of undertreatment. Thus, the therapeutic conundrum of the PVSG, that treatment by phlebotomy alone resulted in a higher incidence of thrombosis during the first 3 years of therapy while chemotherapy or radiotherapy resulted in a high incidence of malignancy thereafter, 243 was not a conundrum at all but rather the consequence of inadequate reduction of the red cell mass to begin with. Furthermore, since in polycythemia vera red cell production is tightly linked to the iron supply,325 differences in phlebotomy requirements were not a function of a difference in disease activity243 but rather in the extent of iron stores or availability. Unfortunately, based on a recent survey, an inappropriately high threshold for phlebotomy therapy is still being

employed by many American hematologists.7

Thrombocytosis and polycythemia vera: platelets at your finger tips
Fact versus fiction Perhaps no other medical condition has caused more otherwise astute clinicians to abandon disbelief than thrombocytosis, particularly with respect to its contribution to the coagulopathy of polycythemia vera. The high frequency of vascular occlusion associated with this disease had been recognized for many years159 but not until 1938, in the absence of any proof, was it suggested that thrombocytosis was a cause of major vessel thrombosis, 146 a suggestion subsequently accepted by influential clinicians 145,154,290 without corroborating evidence. There is a particular irony in this since when essential thrombocytosis was first recognized, not only was it called hemorrhagic thrombocythemia326 but many of the patients described actually had unrecognized polycythemia vera.327,328 More importantly, no study to date, either prospective or retrospective, has demonstrated a correlation between platelet number or function and major vessel thrombosis. For example, in the PVSG prospective trial involving 431 patients, there was no correlation between an elevated platelet count and the risk of thrombosis, 243 while a follow-up study employing antiplatelet agents failed to demonstrate a reduction in thrombotic events.329 This should not have been surprising considering the number of retrospective studies that failed to identify a correlation between the platelet count and risk of thrombosis, 87,150,255,330,331 the well-established correlation of thrombosis with an elevated hematocrit level, 322,331 and the failure of the PVSG to ensure adequate reduction of the red cell mass in their patients.72,200 Furthermore, even though a large number of platelet function abnormalities have been identified in polycythemia vera, they did not correlate with the development of thrombosis 332 nor did age in some series. 333 Additionally, even when patients with isolated thrombocytosis were considered, it was difficult to
Top Introduction The pathogenesis of... The diagnosis of polycythemia... Anecdote as paradigm: the... Survival with polycythemia... Phlebotomy and polycythemia... Thrombocytosis and polycythemia... The management of polycythemia... References

incriminate the platelet count as a thrombotic risk factor. For example, most patients with familial thrombocytosis did not have an increased incidence of thrombosis 334-338 nor did those with reactive thrombocytosis339 and in the only prospective, controlled study of essential thrombocytosis to date, the incidence of thrombosis in untreated patients was not greater than in the control population. 340 Part of the problem with defining the role of thrombocytosis as a thrombotic risk factor has been the intuition that it must be. This has led to reportorial bias with the publication and uncritical acceptance of anecdotal and incompletely studied case reports of unexpected thrombotic events occurring in association with thrombocytosis.242,341343 These, unfortunately, not only fail to establish a cause and effect relationship but also merely provide a numerator without any denominator. As an example, when the factors associated with hepatic vein thrombosis were evaluated retrospectively, it was found that this event was actually preceded by a high hematocrit level and followed by thrombocytosis.249 A second issue has been failure to consider other causes for hypercoagulability within the population under study such as the antiphospholipid syndrome 344 or cardiovascular risk factors.345,346 In this regard, it is worth noting that the frequency of coronary artery thrombosis in the PVSG-01 trial243 was more in keeping with the latter than the frequency found by others for polycythemia vera patients in the absence of atherosclerotic disease. 253 Indeed, when one considers the vaso-occlusive havoc initiated by heparin-induced thrombocytopenia or thrombotic thrombocytopenic purpura, it becomes immediately obvious that platelet number alone is not a critical determinant of hypercoagulability. Hemorrhage and microvascular thrombosis However, there is definitely a role for platelets in the coagulopathy that complicates polycythemia vera. With respect to bleeding, it has been established that platelet counts of more than 1 000 000/µL were associated with a hemorrhagic diathesis regardless of the cause.347,348 This was thought to be due to a reduction in high-molecular-weight von Willebrand multimers owing to their adsorption to platelets 349 and was reversible with a reduction in platelet number350 or treatment with DDAVP. 351 Equally important, and paradoxically, considering its effect

on von Willebrand multimers, thrombocytosis can cause microvascular arteriolar thrombosis. This is manifest most often in peripheral vessels by the syndrome of erythromelalgia, 352,353 and in the nervous system by a constellation of symptoms such as headache or ocular disturbances, often migrainous in type, amaurosis fugax, vertigo, diplopia, vertigo, hemiparesis, paresthesias, numbness, dysarthria, aphasia, and syncope. 354 Usually transient and rarely progressive, these symptoms are distressing to patients and alarming to their physicians. Not infrequently, they may occur as the presenting manifestation of polycythemia vera and if superimposed on an already compromised vascular system could lead to a stroke, myocardial infarction, or peripheral gangrene.352,355 While the mechanism for platelet-associated microvascular occlusion is unknown, it is associated with increased platelet thromboxane B formation 356 and increased platelet turnover. 357,358 Both can be reversed or prevented by aspirin-induced platelet inactivation or a reduction in platelet count, though not necessarily to normal, suggesting that both platelet activation and platelet number are important. However, as demonstrated clinically,329 unless the red cell mass is appropriately reduced, antiplatelet therapy or chemotherapy will be futile, and this stipulation should be mandatory for any prospective study of the effect of antiplatelet therapy on large vessel thrombosis in polycythemia vera.

The management of polycythemia vera: first, do no harm
Top From the foregoing it is clear that Introduction the diagnosis and management of The pathogenesis of... polycythemia vera continue to The diagnosis of polycythemia... Anecdote as paradigm: the... present formidable problems: Survival with polycythemia... polycythemia vera is a clonal Phlebotomy and polycythemia... disorder for which there is as yet Thrombocytosis and polycythemia... no clinically validated clonal The management of polycythemia... References marker; trilineage hyperplasia is the hallmark of polycythemia vera but clinically the disease can mimic not only its companion myeloproliferative disorders, idiopathic myelofibrosis, and essential thrombocytosis, but also nonclonal causes of erythrocytosis; the disease is uncommon but its presenting manifestations are protean, ranging from

intractable pruritus to the Budd-Chiari syndrome. Moreover, due to plasma volume expansion, splenomegaly, or hemorrhage, erythrocytosis, the one feature that sets polycythemia vera apart from the other chronic myeloproliferative disorders, may not be clinically obvious.132 Furthermore, contrary to conventional wisdom, the natural history of polycythemia vera has not been completely defined and neither staging criteria nor the factors affecting prognosis have been established even though it is well documented that the clinical course of the disorder is variable and that age and sex have an important influence in this regard. While the currently accepted diagnostic criteria for polycythemia vera are useful for protocol studies, they do not define the limits of the disease, and a recent poll suggests considerable ambivalence among hematologists as to the optimal approach to the diagnosis of the disease as well as to its treatment. 7 Remarkably, although erythrocytosis is the one feature that distinguishes polycythemia vera from its companion myeloproliferative disorders and the most frequent cause of serious complications, the utility of red cell mass and plasma volume determinations for diagnosis has been questioned as has the effectiveness of phlebotomy therapy. Unfortunately, the only prospective, controlled clinical trial of the disorder to date with respect to phlebotomy therapy, that of the PVSG, was flawed because the target hematocrit level chosen for phlebotomy therapy was too high. 200 Thus, the therapeutic dilemma that patients treated initially with phlebotomy had an unacceptably high incidence of early thromboses while those treated with chemotherapy or 32P later had a high incidence of leukemia, lymphoma, or cancer,243 is probably more apparent than real, at least with respect to the phlebotomy group. In the same fashion, given the lack of attention to reducing blood viscosity in this disorder, it can be seriously questioned whether a prior history of thrombosis and advanced age are truly risk factors for thrombosis in polycythemia vera patients.331 Certainly, neither chemotherapy nor radiotherapy has proved superior to phlebotomy in preventing thrombosis but both have proved to be more toxic.244 Furthermore, since polycythemia vera appears to be a myeloaccumulative disorder rather than a myeloproliferative one, at least with respect to the erythrocytosis and a disorder that is often indolent and of long duration, its treatment should be commensurate with that behavior.

The first issue with respect to management is diagnosis and it should be obvious that it is not possible to accurately estimate the red cell mass from the hematocrit level when polycythemia vera is a diagnostic consideration and the hematocrit level is less than 60% in a man or 50% in a woman. Measurement of the red cell mass and plasma volume by isotope dilution should be a standard of care but unfortunately this standard is more often honored in the breach than in the observance. In some locales, bogus medical economics have been allowed to dictate the availability of these procedures, which can only be seen as an abdication of our professional responsibilities as hematologists. While elevation of the red cell mass does not establish the diagnosis of polycythemia vera, the diagnosis cannot be made in its absence. Even if a clonal assay for polycythemia vera were available, such an assay would not abrogate the need for red cell mass and plasma volume determinations in this disease any more than the HFE assay for hemochromatosis has abrogated the need for serum transferrin saturation measurements as a guide to both diagnosis and therapy. Reduction of the red cell mass and maintaining it at a safe level by phlebotomy (hematocrit level of < 45% in men and < 42% in women and < 36% during pregnancy) is the first principle of therapy in polycythemia vera. Venesection is a safe and immediately effective therapy and its desired side effect, iron deficiency, is not a liability,310 claims that cannot be made for any of the surrogate therapies for polycythemia vera that have been proposed to date. Reduction of the red cell mass and maintaining it at a physiologic level removes a major source of complications and may also alleviate systemic hypertension and pruritus359 and reduce splenomegaly.161,360 For many patients, no other therapy may be necessary for many years. Aspirin or anticoagulants such as coumadin are not substitutes for adequate phlebotomy; low doses of aspirin block urate excretion while titration of the coumadin dose can be difficult if the red cell mass is not controlled. Occasionally, with blood loss or overzealous phlebotomy, symptomatic anemia can ensue. Judicious iron replacement can accelerate the recovery process but too much iron will result in an explosive increase in red cell mass. The other complications of polycythemia vera (Table 4), with the exception of leukemic transformation, represent the consequences of cell accumulation manifested as organ enlargement,

microvascular occlusive or hemorrhagic phenomenon, hyperuricemia, or cytokine-mediated events such as pruritus and acid-peptic disease, but their treatment need not necessarily be genotoxic. For example, aspirin alone353,361 or anagrelide362 may be sufficient to combat the microvascular occlusive syndrome associated with thrombocytosis. It is, of course, important to remember that polycythemia vera patients are not immune to other illnesses causing thrombosis. Similarly, a modest leukocytosis requires no correction; however, if progressive, leukocytosis is a harbinger of extramedullary hematopoiesis or disease acceleration. In which case, the leukocytosis can serve as a guide to disease control following the institution of therapy. Table 4. The complications of polycythemia View this table: vera [in this window] [in a new window]

Because there is currently no clonal marker for polycythemia vera, it is currently impossible to determine if a particular therapy is curative or merely palliative. In this regard, the long natural history of the disorder and the infrequent and unpredictable occurence of spontaneous leukemic transformation make it difficult to establish the superiority of any therapy or to recommend a potentially curative therapy such as allogeneic bone marrow transplantation that carries an immediate obligate mortality as well as the potential for substantial chronic morbidity. We are, however, fortunate to have a variety of symptomatic remedies for the many complications of polycythemia vera because no single remedy has proved completely effective for any of them. However, many of these remedies are not without risk and have their own unique toxicities. For example, pruritus can prove to be so intractable to phlebotomy, antihistamines, or psoralen-activated light therapy that resort must be made to suppression of hematopoiesis with alpha interferon, hydroxyurea, or even busulphan. Splenomegaly due to extramedullary hematopoiesis can be similarly difficult to manage. Yet attempts to avoid the complications of cell accumulation by chemotherapy or irradiation have not been without substantial toxicity,163,200,244 and while alpha interferon is a promising agent in this regard,363 it can have substantial side effects, particularly in the

elderly 364 ; it is also unknown whether this agent can alter the natural history of polycythemia vera. Tolerance to alpha interferon may be aided by starting with a low dose (500 000 U, 3 times per week) and escalating slowly; the addition of an antidepressant has also been found helpful. 365 Although alpha interferon is expensive and its side effects can be debilitating, it has not been demonstrated to cause permanent marrow damage. The same may not be true for hydroxyurea,212,214,366 although the evidence is not entirely conclusive at this time. However, this was also the situation initially for other cytotoxic agents that subsequently proved to be leukemogenic in this disease. Therefore, it seems prudent to employ hydroxyurea only when other remedies have failed and to avoid long-term exposure whenever possible. Since few physicians see many of these patients, the concerns described above emphasize the need to gain greater insight into the natural history of polycythemia vera and to reinitiate prospective, controlled multicenter clinical trials using the wisdom gained from such initiatives as the Cooperative Study of Sickle Cell Disease367 and the PVSG. Until such a time as those goals are realized, we can do no better than to heed the advice of William Dameshek, a proponent of phlebotomy therapy in polycythemia vera: "There seems to be a tendency in medical practice by no means limited to hematologists to treat almost every condition as vigorously as possible. In hematology, this consists in attempting to change an abnormal number whether this number is hemoglobin, hematocrit, WBC, platelet count to normal values whether the patient needs it or not!" 238

Submitted December 28, 2001; accepted July 15, 2002. Prepublished online as Blood First Edition Paper, August 8, 2002; DOI 10.1182/blood-2001-12-0349. Reprints: Jerry L. Spivak, Traylor 924, Johns Hopkins University School of Medicine, 720 Rutland Ave, Baltimore, MD 21205; e-mail: jlspivak@jhmi.edu.

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913-916[Abstract].
Top Introduction The pathogenesis of... The diagnosis of polycythemia... Anecdote as paradigm: the... Survival with polycythemia... Phlebotomy and polycythemia... Thrombocytosis and polycythemia... The management of polycythemia... References

2. Adamson JW, Singer JW, Catalano P, et al. Polycythemia vera: further in vitro studies of hematopoietic regulation. J Clin Invest. 1980;66:1363-1368[Medline].

3. Vaquez H. Sur une Forme Speciale De Cyanose S'Accompagnant D' Hyperglobulie Excessive Et Peristante. C R Soc Biol (Paris). 1892;44:384-388. 4. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992;48:20-26[Medline]. 5. Ania BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 19351989. Am J Hematol. 1994;47:89-93[Medline]. 6. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol. 1997;15:173-189[CrossRef][Medline]. 7. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group. Blood. 2002;99:1144[Abstract/Free Full Text]. 8. Berlin NI, Lawrence JH, Lee HC. The life span of the red blood cell in chronic leukemia and polycythemia. Science. 1951;114:385-387. 9. Eaves AC, Henkelman DH, Eaves CJ. Abnormal erythropoiesis in the myeloproliferative disorders: an analysis of underlying cellular and humoral mechanisms. Exp Hematol. 1980;8(suppl 8):235-247[Medline]. 10. Lawrence JH, Elmlinger PJ, Fulton G. Oxygen and the control of red cell production in primary and secondary polycythemia: effects on iron turnover pattern with Fe59 as a tracer. Cardiologia. 1952;21:337-346. 11. Spivak JL, Cooke CR. Polycythemia vera in an anephric man. Am J Med Sci. 1976;272:339-344[Medline].

12. Falconer E. Treatment of polycythemia: the reticulocyte response to venesection, phenylhydrazin and radiation. Ann Intern Med. 1933;7:172189. 13. Stephens DJ, Kaltreider N. The therapeutic use of venesection in polycythemia. Ann Intern Med. 1937;10:1565-1581. 14. Carneskog J, Kutti J, Wadenvik H, Lundberg PA, Lindstedt G. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 1998;60:278-282[Medline]. 15. Prchal JF, Axelrad AA. Bone marrow responses in polycythemia vera [letter]. N Engl J Med. 1974;290:1382[Medline]. 16. Golde DW, Koeffler HP, Adamson JW. Polycythemia vera: mechanisms and management. Ann Intern Med. 1981;95:7187[Medline]. 17. Cashman J, Henkelman D, Humphries K, Eaves C, Eaves A. Individual BFU-E in polycythemia vera produce both erythropoietin dependent and independent progeny. Blood. 1983;61:876-884[Abstract]. 18. Papayannopoulou T, Buckley J, Nakamoto B, et al. Hb F production of endogenous colonies of polycythemia vera. Blood. 1979;53:446454[Abstract]. 19. Eid J, Ebert RF, Gesell MS, Spivak JL. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders. Proc Natl Acad Sci U S A. 1987;84:532-536[Medline]. 20. de Wolf JT, Beentjes JA, Esselink MT, et al. In polycythemia vera human interleukin 3 and granulocyte-macrophage colony-stimulating factor enhance erythroid colony growth in the absence of erythropoietin. Exp Hematol. 1989;17:981-983[Medline]. 21. Dai CH, Krantz SB, Green WF, Gilbert HS. Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol. 1994;86:12-21[Medline]. 22. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994;83:99-112[Abstract/Free Full Text]. 23. Wickrema A, Chen F, Namin F, et al. Defective expression of the

SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999;27:11241132[CrossRef][Medline]. 24. Dai CH, Krantz SB, Sawyer ST. Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood. 1997;89:35743581[Abstract/Free Full Text]. 25. Andersson P, LeBlanc K, Eriksson BA, Samuelsson J. No evidence for an altered mRNA expression or protein level of haematopoietic cell phosphatase in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythaemia vera. Eur J Haematol. 1997;59:310-317[Medline]. 26. Asimakopoulos FA, Hinshelwood S, Gilbert JG, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997;14:12151222[CrossRef][Medline]. 27. Sui X, Krantz S, Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood. 1997;90:651-657[Abstract/Free Full Text]. 28. Dai C, Krantz SB. Increased expression of the INK4a/ARF locus in polycythemia vera. Blood. 2001;97:3424-3432[Abstract/Free Full Text]. 29. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp Hematol. 2001;29:694-702[CrossRef][Medline]. 30. Gaidano G, Guerrasio A, Serra A, et al. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia. 1993;7:946953[Medline]. 31. Chen Z, Notohamiprodjo M, Guan XY, et al. Gain of 9p in the pathogenesis of polycythemia vera. Genes Chromosomes Cancer. 1998;22:321-324[CrossRef][Medline]. 32. Najfeld V, Montella L, Scalise A, Fruchtman SM. Exploring polycythemia vera with FISH: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol. 2002;119:1-9[CrossRef][Medline]. 33. Nunez C, Bashein AM, Brunet CL, et al. Expression of the imprinted tumour-suppressor gene H19 is tightly regulated during normal haematopoiesis and is reduced in haematopoietic precursors of patients

with the myeloproliferative disease polycythaemia vera. J Pathol. 2000;190:61-68[CrossRef][Medline]. 34. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236[CrossRef][Medline]. 35. Dai CH, Krantz SB, Koury ST, Kollar K. Polycythemia vera. IV. Specific binding of stem cell factor to normal and polycythemia vera highly purified erythroid progenitor cells. Br J Haematol. 1994;88:497505[Medline]. 36. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormoneindependent activation and tumorigenicity. Nature. 1990;348:647649[Medline]. 37. Means RT, Krantz SB, Gilbert HS. Erythropoietin receptors in polycythemia vera. J Clin Invest. 1989;84:1340-1344[Medline]. 38. Broudy VC, Kin N, Papayannopoulou T. Erythropoietin receptors in polycythemia vera. Exp Hematol. 1990;18:576a. 39. Hess G, Rose P, Gamm H, et al. Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol. 1994;88:794-802[Medline]. 40. Lu L, Ge Y, Li ZH, et al. Retroviral transfer of the recombinant human erythropoietin receptor gene into single hematopoietic stem/progenitor cells from human cord blood increases the number of erythropoietin-dependent erythroid colonies. Blood. 1996;87:525534[Abstract/Free Full Text]. 41. Longmore GD, Pharr P, Neumann D, Lodish HF. Both megakaryocytopoiesis and erythropoiesis are induced in mice infected with a retrovirus expressing an oncogenic erythropoietin receptor. Blood. 1993;82:2386-2395[Abstract]. 42. Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992;257:1138-1141[Medline]. 43. Schwall R. A truncated erythropoietin receptor and cell death. Science. 1993;259:696[Medline]. 44. Nakamura Y, Nakauchi H. A truncated erythropoietin receptor and cell death: a reanalysis. Science. 1994;264:588-589[Medline].

45. Nakamura Y, Tokumoto Y, Nakauchi H. Role of a truncated erythropoietin receptor for erythroid differentiation. Biochem Biophys Res Commun. 1996;218:205-209[CrossRef][Medline]. 46. Chiba S, Takahashi T, Takashita K, et al. Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera. Blood. 1997;90:97-104[Abstract/Free Full Text]. 47. Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-571[Abstract/Free Full Text]. 48. Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood. 1991;77:1228-1233[Abstract]. 49. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378-381[Medline]. 50. Spivak JL, Ferris DK, Fisher J, et al. Cell cycle-specific behavior of erythropoietin. Exp Hematol. 1996;24:141-150[Medline]. 51. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576-1582[Abstract/Free Full Text]. 52. Fairbairn LJ, Cowling GJ, Reipert BM, Dexter TM. Suppression of apoptosis allows differentiation and development of a multipotent hemopoietic cell line in the absence of added growth factors. Cell. 1993;74:823-832[Medline]. 53. Carroll M, Zhu Y, D'Andrea AD. Erythropoietin-induced cellular differentiation requires prolongation of the G1 phase of the cell cycle. Proc Natl Acad Sci U S A. 1995;92:2869-2873[Abstract]. 54. Gregoli PA, Bondurant MC. The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. Blood. 1997;90:630640[Abstract/Free Full Text]. 55. Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 1995;86:877-882[Abstract/Free Full Text]. 56. Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding

protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood. 1997;89:18621869[Abstract/Free Full Text]. 57. Damen JE, Krosl J, Morrison D, Pelech S, Krystal G. The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum. Blood. 1998;92:425-433[Abstract/Free Full Text]. 58. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood. 1998;92:4-10[Abstract/Free Full Text]. 59. Borge OJ, Ramsfjell V, Cui L, Jacobsen SE. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+. Blood. 1997;90:2282-2292[Abstract/Free Full Text]. 60. Young JC, Bruno E, Luens KM, et al. Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34+ progenitor cells from single CD34+Thy-1+Lin- primitive progenitor cells. Blood. 1996;88:1619-1631[Abstract/Free Full Text]. 61. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpldeficient mice. Blood. 1996;88:803-808[Abstract/Free Full Text]. 62. Sawai N, Koike K, Ito S, et al. Neutrophilic cell production by combination of stem cell factor and thrombopoietin from CD34(+) cord blood cells in long-term serum-deprived liquid culture. Blood. 1999;93:509-518[Abstract/Free Full Text]. 63. Papayannopoulou T, Brice M, Farrer D, Kaushansky K. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol. 1996;24:660-669[Medline]. 64. Ratajczak MZ, Ratajczak J, Marlicz W, et al. Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis. Br J Haematol. 1997;98:8-17[Medline]. 65. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369-4383[Abstract/Free Full Text]. 66. Cocault L, Bouscary D, Le Bousse Kerdiles MC, et al. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood. 1996;88:16561665[Abstract/Free Full Text].

67. Wendling F, Varlet P, Charon M, Tambourin P. MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology. 1986;149:242-246[Medline]. 68. Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990;63:11371147[Medline]. 69. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94:2555-2561[Abstract/Free Full Text]. 70. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94:365-367[Abstract/Free Full Text]. 71. Osler W. Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci. 1903;126:176-201. 72. Wasserman L. The management of polycythemia vera. Br J Haematol. 1971;21:371-376[Medline]. 73. Ellis JT, Silver RT, Coleman M, Geller SA. The bone marrow in polycythemia vera. Semin Hematol. 1975;12:433-444[Medline]. 74. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood. 1988;72:386-395[Abstract]. 75. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986;23:144155[Medline]. 76. Kilbridge TM, Fried W, Heller P. The mechanism by which plethora suppresses erythropoiesis. Blood. 1969;33:104-113[Medline]. 77. Cazzola M, Guarnone R, Cerani P, et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood. 1998;91:2139-2145[Abstract/Free Full Text]. 78. Haga P, Cotes PM, Till JA, Minty BD, Shinebourne EA. Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease. Blood. 1987;70:822-826[Abstract].

79. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC. Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol. 1990;75:188194[Medline]. 80. Dainiak N, Hoffman R, Lebowitz AI, et al. Erythropoietin-dependent primary pure erythrocytosis. Blood. 1979;53:1076-1084[Abstract]. 81. Eridani S, Dudley JM, Sawyer BM, Pearson TC. Erythropoietic colonies in a serum-free system: results in primary proliferative polycythaemia and thrombocythaemia. Br J Haematol. 1987;67:387391[Medline]. 82. Turhan AG, Cashman JD, Eaves CJ, Humphries RK, Eaves AC. Variable expression of features of normal and neoplastic stem cells in patients with thrombocytosis. Br J Haematol. 1992;82:50-57[Medline]. 83. Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. Br J Haematol. 1993;83:192-197[Medline]. 84. Ciaudo M, Hadjez JM, Teyssandier I, et al. Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia. Hematol Cell Ther. 1998;40:171-174[Medline]. 85. Lemoine F, Najman A, Baillou C, et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986;68:996-1002[Abstract]. 86. Weinberg RS, Worsley A, Gilbert HS, et al. Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia: only polycythemia vera has endogenous colonies. Leuk Res. 1989;13:331-338[Medline]. 87. Szur L, Lewis SM, Goolden AWG. Polycythemia vera and its treatment with radioactive phosphorus. Q J Med. 1959;28:397-424. 88. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339-351[Medline]. 89. Temerinac S, Klippel S, Strunck E, et al. Cloning of PVR-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 2000;95:25692579[Abstract/Free Full Text].

90. Bessman DJ. Microcytic polycythemia: frequency of nonthalassemic causes. JAMA. 1977;238:2391-2392[Medline]. 91. Gilbert HS, Goldberg R, Ward L. Increased circulating neutrophils with surface receptor activity for immunoglobulin G in polycythemia vera and myeloid metaplasia. Blood. 1979;53:1106-1113[Abstract]. 92. Samuelsson J, Forslid J, Hed J, Palmblad J. Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders. Br J Haematol. 1994;87:464-470[Medline]. 93. Cooper B, Ahern D. Characterization of the platelet prostaglandin D2 receptor: loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. J Clin Invest. 1979;64:586590[Medline]. 94. Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood. 1979;54:12581271[Abstract]. 95. Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med. 1982;306:381386[Abstract]. 96. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572-580[Abstract/Free Full Text]. 97. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90:4031-4038[Abstract/Free Full Text]. 98. Moliterno AR, Silver RT, Spivak JL. A diagnostic assay for polycythemia vera. Blood. 2001;96:512a. 99. Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur J Haematol. 2000;65:170-174[CrossRef][Medline]. 100. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera. Blood. 2001;98:470a. 101. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc. 1991;66:287-299[Medline].

102. Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet. 1987;25:233245[Medline]. 103. el Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood. 1997;89:128134[Abstract/Free Full Text]. 104. Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 1996;88:59-65[Abstract/Free Full Text]. 105. Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol. 1997;98:512519[Medline]. 106. Gilbert HL, Acharya J, Pearson TC. Implications for the use of Xchromosome inactivation patterns and their relevance to the myeloproliferative disorders. Eur J Haematol. 1998;61:282283[Medline]. 107. Prchal JT, Sokol L. "Benign erythrocytosis" and other familial and congenital polycythemias. Eur J Haematol. 1996;57:263-268[Medline]. 108. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28:5762[CrossRef][Medline]. 109. Blum A, Zbar M. Relative polycythemia. Arch Intern Med. 1959;104:385-389. 110. Watts EJ, Lewis SM. Spurious polycythaemia a study of 35 patients. Scand J Haematol. 1983;31:241-247[Medline]. 111. Berlin NI, Lewis SM. Measurement of total RBC volume relative to lean body mass for diagnosis of polycythemia. Am J Clin Pathol. 2000;114:922-926[Medline]. 112. Spivak JL. The clinical physiology of erythropoietin. Semin Hematol. 1993;30:2-11. 113. Verel D. Blood volume changes in cyanotic congenital heart disease and polycythemia rubra vera. Circulation. 1961;23:749-753.

114. Weil JV, Jamieson G, Brown DW, et al. The red cell mass-arterial oxygen relationship in normal man. J Clin Invest. 1968;47:16271639[Medline]. 115. Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med. 1978;298:972-973[Medline]. 116. Sanchez C, Merino C, Figallo M. Simultaneous measurement of plasma volume and cell mass in polycythemia of high altitude. J Appl Physiol. 1970;28:775-778[Medline]. 117. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebocontrolled trial. Ann Intern Med. 1989;110:108-114[Medline]. 118. Besa EC, Gorshein D, Gardner FH. Androgens and human blood volume changes: comparison in normal and various anemic states. Arch Intern Med. 1974;133:418-425[Medline]. 119. Sawka MN, Dennis RC, Gonzalez RR, et al. Influence of polycythemia on blood volume and thermoregulation during exerciseheat stress. J Appl Physiol. 1987;62:912-918[Abstract/Free Full Text]. 120. Singh A, Eckardt KU, Zimmermann A, et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest. 1993;91:251-256[Medline]. 121. Murray JF. Arterial studies in primary and secondary polycythemic disorders. J Clin Invest. 1964;435-449. 122. Campbell A, Emery EW, Godlee JN, Prankerd TAJ. Diagnosis and treatment of primary polcy-thaemia. Lancet. 1970;1:10741077[Medline]. 123. Smith HP, Arnold HR, Whipple GH. Comparative values of Welcker, carbon monoxide and dye methods for blood volume determinations. accurate estimation of absolute blood volume. Am J Physiol. 1921;56:336-360. 124. Gibson JG, Seligman A, Peacock WC, et al. The distribution of red cells and plasma in large and minute vessels of the normal dog, determined by radioactive isotopes of iron and iodine. J Clin Invest. 1946;5:848-857. 125. Ebert R, Stead EA. Demonstration that the cell plasma ratio of blood contained in minute vessels is lower than that of venous blood. J Clin Invest. 1941;20:317-321.

126. Berson S, Yalow RS. The use of K42 or P32 labeled erythrocytes and I131 tagged human serum albumin in simultaneous blood volume determinations. J Clin Invest. 1952;31:572-580. 127. Retzlaff JA, Tauxe WN, Kiely JM, Stroebel CF. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood. 1969;33:649-661[Medline]. 128. Fahraeus R, Lindqvuist T. The viscosity of the blood in narrow capillary tubes. Am J Physiol. 1931;96:562-568. 129. Jonsson V, Bock JE, Nielsen JB. Significance of plasma skimming and plasma volume expansion. J Appl Physiol. 1992;72:20472051[Abstract/Free Full Text]. 130. Huber H, Lewis SM, Szur L. The influence of anaemia, polycythaemia and splenomegaly on the relationship between venous haematocrit and red-cell volume. Br J Haematol. 1964;10:567-575. 131. Zhang B, Lewis SM. The splenomegaly of myeloproliferative disorders: effects on blood volume and red blood count. Eur J Haematol. 1989;42:250-253[Medline]. 132. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: an unrecognized diagnosis. Am J Med. 1997;102:1420[CrossRef][Medline]. 133. Lawrence JH, Berlin NI, Huff RL. The nature and treatment of polycythemia. Medicine. 1953;32:323-388. 134. Barosi G, Cazzola M, Frassoni F, Orlandi E, Stefanelli M. Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J Haematol. 1981;48:263-272[Medline]. 135. Pettit JE, Lewis SM, Nicholas AW. Transitional myeloproliferative disorder. Br J Haematol. 1979;43:167-184[Medline]. 136. Najean Y, Arrago JP, Rain JD, Dresch C. The `spent' phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis. Br J Haematol. 1984;56:163-170[Medline]. 137. Stead EA, Ebert RF. Relationship of the plasma volume and the cell plasma ratio to the total red cell volume. Am J Physiol. 1941;132:411417.

138. Strumia MM, Strumia PV, Dugan A. Significance of measurement of plasma volume and of indirect estimation of red cell volume. Transfusion. 1968;8:197-209[Medline]. 139. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995;89:748-756[Medline]. 140. Pearson TC, Glass UH, Wetherley-Mein G. Interpretation of measured red cell mass in the diagnosis of polycythaemia. Scand J Haematol. 1978;21:153-162[Medline]. 141. Fairbanks VF, Klee GG, Wiseman GA, et al. Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis. 1996;22:169-186[CrossRef][Medline]. 142. Fairbanks V. Polycythemia vera: the packed cell volume and the curious logic of the red cell mass. Hematology. 2000;4:381395[Medline]. 143. Fairbanks VF, Tefferi A. Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to `apparent polycythemia.' Eur J Haematol. 2000;65:285-296[CrossRef][Medline]. 144. Hess CH, Ayers CR, Sandusky WR, et al. Mechanism of dilutional anemia in massive splenomegaly. Blood. 1976;47:629-644[Abstract]. 145. Wasserman LR. Polycythemia vera its course and treatment relation to myeloid metaplasia and leukemia. Bull N Y Acad Med. 1954;30:343-375. 146. Rosenthal N, Bassen F. Course of polycythemia. Arch Int Med. 1938;62:903-917. 147. Minot G, Buckman TE. Erythremia (polycythemia vera): the development of anemia; the relation to leukemia; consideration of the basal metabolism, blood formation and destruction and fragility of the red cells. Am J Med Sci. 1923;166:469-488. 148. Dameshek W. Physiopathology and course of polycythemia vera as related to therapy. JAMA. 1950;142:790-797. 149. Perkins J, Israels MCG, Wilkinson JF. Polycythemia vera: clinical studies on a series of 127 patients managed without radiation therapy. Q J Med. 1964;33:499-518.

150. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol. 1985;61:657-666[Medline]. 151. Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67:285-291[Medline]. 152. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375. 153. Glasser RM, Walker RI. Transitions among the myeloproliferative disorders. Ann Intern Med. 1969;71:285-307[Medline]. 154. Moschcowitz E. Essays on the biology of disease. J Mt Sinai Hosp. 1944;6:232-235. 155. Pollycove M, Winchell HS, Lawrence JH. Classification and evolution of patterns of erythropoiesis in polycythemia vera as studied by iron kinetics. Blood. 1966;28:807-829[Medline]. 156. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513-523. 157. Silverstein MN. The evolution into and the treatment of late stage polycythemia vera. Semin Hematol. 1976;13:79-84[Medline]. 158. Roberts BE, Miles DW, Woods CG. Polycy-thaemia vera and myelosclerosis: a bone marrow study. Br J Haematol. 1969;16:7585[Medline]. 159. Harrop G. Polycythemia. Medicine. 1928;7:291-344. 160. Tinney WS, Hall BE, Giiffin HZ. The liver and spleen in polycythemia vera. Proc Staff Meetings Mayo Clin. 1943;18:46-47. 161. Hines L, Darnall W. The control of polycythemia vera by venesection. Ann J Med Sci. 1943;206:434-435. 162. Pettit JE, Lewis SM, Williams ED, et al. Quantitative studies of splenic erythropoiesis in polycythaemia vera and myelofibrosis. Br J Haematol. 1976;34:465-475[Medline]. 163. Modan B, Lilienfeld AM. Polycythemia vera and leukemia role of radiation treatment. Medicine. 1965;44:305-339. the

164. Silverstein MN. Postpolycythemia myeloid metaplasia. Arch Intern Med. 1974;134:113-117[Medline]. 165. Kurnick JE, Mahmood T, Napoli N, Block MH. Extension of myeloid tissue into the lower extremities in polycythemia. Am J Clin Pathol. 1980;74:427-431[Medline]. 166. Rigby PG, Leavell BS. Polycythemia vera. Arch Intern Med. 1960;5:100-105. 167. Tubiana M, Flamant R, Attie E, Hayat M. A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients). Blood. 1968;32:536548[Medline]. 168. Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood. 1985;65:803809[Abstract]. 169. Najean Y, Rain J. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377[Abstract/Free Full Text]. 170. Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis pathophysiological implications. Am J Hematol. 1998;59:133142[CrossRef][Medline]. 171. Johnston JB, Dalal BI, Israels SJ, et al. Deposition of transforming growth factor-beta in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-beta by leukemic cells. Am J Clin Pathol. 1995;103:574-582[Medline]. 172. Frey BM, Rafii S, Teterson M, et al. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160:691-699[Abstract/Free Full Text]. 173. Leonard BJ, Israels MCG, Wilkinson JF. Myelosclerosis: a clinicopathological study. Q J Med. 1957;26:131-149. 174. Pereira A, Cervantes F, Brugues R, Rozman C. Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol. 1990;44:9599[Medline].

175. Korst D, Clatanoff DV, Schilling RF. On myelofibrosis. Arch Intern Med. 1955;97:169-183. 176. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group [see comments]. Br J Haematol. 1994;86:233-235[Medline]. 177. Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS. A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med. 1962;57:73-84. 178. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970[Abstract/Free Full Text]. 179. Burston J, Pinniger JL. The reticulin content of bone marrow in haematological disorders. Br J Haematol. 1963;9:172-184. 180. Najean Y, Deschamps A, Dresch C, et al. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow-up. Cancer. 1988;61:89-95[Medline]. 181. Ikkala E, Rapola J, Kotilainen M. Polycythaemia vera and myelofibrosis. Scand J Haemat. 1967;4:453-464[Medline]. 182. Kreft A, Nolde C, Busche G, et al. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol. 2000;64:32-41[CrossRef][Medline]. 183. Najean Y, Cacchione R, Castro-Malaspina H, Dresch C. Erythrokinetic studies in myelofibrosis: their significance for prognosis. Br J Haematol. 1978;40:205-217[Medline]. 184. Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol. 1984;33:453-459[Medline]. 185. Pettit JE, Lewis SM, Goolden AWG. Polycythemia vera: transformation to myelofibrosis and subsequent reversal. Scand J Haematol. 1978;20:63-69[Medline]. 186. Pamphilon DH, Creamer P, Keeling DH, Prentice AG. Restoration of active haemopoiesis in a patient with myelofibrosis and subsequent termination in acute myeloblastic leukaemia: case report and review of the literature. Eur J Haematol. 1987;38:279-283[Medline].

187. Lohmann TP, Beckman EN. Progressive myelofibrosis in agnogenic myeloid metaplasia. Arch Pathol Lab Med. 1983;107:593-594[Medline]. 188. Hasselbalch H, Lisse I. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur J Haematol. 1991;46:285-289[Medline]. 189. Szur L, Lewis SM. The haematological complications of polycythaemia vera and treatment with radioactive phosphorus. Br J Radiol. 1966;39:122-130[Medline]. 190. Bouroncle B, Doan CA. Myelofibrosis: clinical, hematologic and pathologic study of 110 patients. Am J Med Sci. 1962;243:697-715. 191. Linman J, Bethell F. Agnogenic myeloid metaplasia. Am J Med. 1957;22:107-122. 192. Hoffbrand AV, Chanarin I, Kremenchuzky S, et al. Megaloblastic anaemia in myelosclerosis. Q J Med. 1968;37:493-514. 193. Silverstein MN, Brown AL, Linman J. Idiopathic myeloid metaplasia: its evolution into acute leukemia. Arch Intern Med. 1973;132:709-712[Medline]. 194. Anger B, Haug U, Seidler R, Heimpel H. Polycythemia vera: a clinical study of 141 patients. Blut. 1989;59:493-500[Medline]. 195. Haanen C, Mathe G. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44:75-80[Medline]. 196. Lazzarino M, Morra E, Castello A, et al. Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br J Haematol. 1986;64:227-240[Medline]. 197. Schwartz SO, Ehrlich L. The relationship of polycythemia vera to leukemia: a critical review. Acta Med Scand. 1950;4:129-147. 198. Osgood EE. Contrasting incidence of acute monocytic and granulocytic leukemias in P32-treated patients with polycythemia vera and chronic lymphocytic leukemia. J Lab Clin Med. 1964;64:560-573. 199. Halnan KE, Russell MH. Comparison of survival and causes of death in patients managed with and without radiotherapy. Lancet. 1965;1:760-763. 200. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence

of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447[Abstract]. 201. Brandt L, Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur J Haematol. 1995;54:21-26[Medline]. 202. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J. 1982;284:449-460[Medline]. 203. Simpson CL, Hempelmann LH, Fuller LM. Neoplasia in children treated with x-rays in infancy for thymic enlargement. Radiology. 1955;64:840-845. 204. Lawrence JH. The control of polycythemia by marrow inhibition. JAMA. 1949;141:13-18. 205. Rosner F. Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer. 1976;37:1033-1036[Medline]. 206. Reimer RR, Hoover R, Fraumeni JF, Young RC. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977;297:177-181[Abstract]. 207. Weinfeld A, Westin J, Ridell B, Swolin B. Polycythaemia vera terminating in acute leukaemia: a clinical, cytogenetic and morphologic study in 8 patients treated with alkylating agents. Scand J Haematol. 1977;19:255-272[Medline]. 208. Michels S, McKenna RW, Arthur DC, Brunning RD. Therapyrelated acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:13641372[Abstract]. 209. Lawrence JH, Winchell HS, Donald WG. Leukemia in polycythemia vera: relationship to splenic myeloid metaplasia and therapeutic radiation dose. Ann Intern Med. 1969;70:763-771[Medline]. 210. Modan B, Modan M. Benign erythrocytosis. Br J Haematol. 1968;14:375-381[Medline]. 211. Najean Y, Triebel F, Dresch C. Pure erythrocytosis: reappraisal of a study of 51 cases. Am J Hematol. 1981;10:129-136[Medline]. 212. Weinfeld A, Swolin B, Westin J. Acute leukaemia after

hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134-139[Medline]. 213. Najean Y, Rain JD, Dresch C, et al. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias." Leuk Lymphoma. 1996;22(suppl 1):111-119[Medline]. 214. Nand S, Messmore H, Fisher SG, et al. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990;34:3236[Medline]. 215. Landaw S. Acute leukemia in polycythemia vera. Semin Hematol. 1976;13:33-48[Medline]. 216. Castleman B, Scully RE, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med. 1973;288:13431350[Medline]. 217. Rosenthal DS, Moloney WC. Occurence of acute leukaemia in myeloproliferative disorders. Br J Hematol. 1977;36:373-382[Medline]. 218. Landaw SA. Acute leukemia in polycythemia vera. Semin Hematol. 1986;23:156-165[Medline]. 219. Conrad ME, Rapport H, Crosby WH. Chronic granulocytic leukemia in the aged. Arch Intern Med. 1965;116:765-775[Medline]. 220. Neu LT, Shuman MA, Brown EB. Polycythemia vera and acute leukemia. Ann Intern Med. 1975;83:672-673[Medline]. 221. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84:937-945[Medline]. 222. Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am. 1993;7:369387[Medline]. 223. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood. 1998;91:3630-3636[Abstract/Free Full Text]. 224. Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol. 1993;11:925-930[Abstract].

225. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152-1157[Abstract/Free Full Text]. 226. Raz I, Shinar E, Polliack A. Pancytopenia with hypercellular bone marrow a possible paraneoplastic syndrome in carcinoma of the lung: a report of three cases. Am J Hematol. 1984;16:403-408[Medline]. 227. DeMent SH, Eggleston JC, Spivak JL. Association between mediastinal germ cell tumors and hematologic malignancies: report of two cases and review of the literature. Am J Surg Pathol. 1985;9:2330[Medline]. 228. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297-303[CrossRef][Medline]. 229. Lundberg WB, Farber LR, Cadman EC, Skeel RT. Spontaneous acute leukemia in polycythemia vera. Ann Intern Med. 1976;84:294295[Medline]. 230. Hazani A, Tatarsky I, Barzilai D. Prolonged remission of leukemia associated with polycythemia vera. Cancer. 1977;40:12971299[Medline]. 231. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a singleinstitution experience with 223 patients. Blood. 2000;95:22262233[Abstract/Free Full Text]. 232. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome:a report on 39 patients. J Clin Oncol. 1993;11:1985-1989[Abstract]. 233. McDonnell JM, Beschorner WE, Staal SP, Spivak JL, Mann RB. Richter's syndrome with two different B-cell clones. Cancer. 1986;58:2031-2037[Medline]. 234. Hirsch EF. Generalized osteosclerosis with chronic polycythemia vera. Arch Pathol. 1935;19:91-97. 235. Tinney WS. Hematologic complications of polycythemia vera. Proc Staff Meetings Mayo Clin. 1943;18:227-231. 236. Tinney WS, Hall BE, Giffin HZ. The prognosis of polycythemia

vera. Proc Staff Meetings Mayo Clin. 1945;20:227-230. 237. Osgood EE. Polycythemia vera: age relationships and survival. Blood. 1965;26:243-256. 238. Wasserman L. The treatment of polycythemia: a panel discussion. Blood. 1968;32:483-499[Medline]. 239. Videbaek A. Polycythemia vera: course and prognosis. Acta Med Scand. 1950;138:179-187. 240. Berger R, Hillion J, Janvier D, Chen Z, Bussel A. t(8;21) prior to acute leukemia. Cancer Genet Cytogenet. 1993;70:125-126[Medline]. 241. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with BuddChiari syndrome. Ann Intern Med. 1985;103:329-334[Medline]. 242. Davis RB. Acute thrombotic complications of myeloproliferative disorders in young adults. Am J Clin Pathol. 1985;84:180-185[Medline]. 243. Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143[Medline]. 244. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664[Medline]. 245. Berlin NI. Treatment of the myeloproliferative disorders with 32P. Eur J Haematol. 2000;65:1-7[CrossRef][Medline]. 246. Stroebel CF, Hall BE, Pease GL. Evaluation of radiophosphorus therapy in primary polycythemia. JAMA. 1951;146:1301-1307. 247. Verel D. The treatment of polycythaemia rubra vera with single doses of radioactive phosphorus. Q J Med. 1958;105:27-43. 248. Wasserman LR. The treatment of polycythemia vera. Semin Hematol. 1976;13:57-78[Medline]. 249. Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr. 1989;67:818825[Medline].

250. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663[Medline]. 251. Silverstein MN, Lainer AP. Polycythemia vera, 1935-1969. Mayo Clin Proc. 1971;46:751-753[Medline]. 252. Zankovich R, Thiele J, Fiessler W-D, Fischer R, Diehl V. Prognostic parameters in polycythemia vera rubra. Med Klin. 1987;82:889-894[Medline]. 253. Barabas AP, Offen DN, Meinhard EA. The arterial complications of polycythaemia vera. Br J Surg. 1973;50:183-187. 254. Wasserman LR, Balcerzak SP, Berk PD, et al. Influence of therapy on causes of death in polycythemia vera. Trans Assoc Am Physicians. 1981;94:30-38[Medline]. 255. Schwarcz TH, Hogan LA, Endean ED, et al. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. J Vasc Surg. 1993;17:518-522[CrossRef][Medline]. 256. Parker RG. Occlusion of the hepatic veins in man. Medicine. 1959;38:369-402. 257. Wasserman L, Gilbert HS. Complications of polycythemia vera. Semin Hematol. 1966;3:199-208. 258. Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol. 1997;97:453456[Medline]. 259. Wells RE, Merrill EW. Influence of flow properties of blood upon viscosity-hematocrit relationship. J Clin Invest. 1962;41:1591-1598. 260. Replogle RL, Kundler H, Gross RE. Studies on the hemodynamic importance of blood viscosity. J Thorac Cardiovasc Surg. 1965;50:658668[Medline]. 261. Begg TB, Hearns JB. Components in blood viscosity: the relative contribution of haematocrit, plasma fibrinogen and other proteins. Clin Sci. 1966;31:87-93[Medline]. 262. Weber FP. Polycythaemia, erythrocytosis and erythraemia. Q J Med. 1908;2:85-134. 263. Brown G, Giffin HZ. Studies of capillaries and blood volume in

polycythemia vera. Am J Med Sci. 1923;166:489-502. 264. Cobb LA, Kramer RJ, Finch CA. Circulatory effects of chronic hypervolemia in polycythemia vera. J Clin Invest. 1960;39:1722-1728. 265. Altschule MD, Volk MC, Henstell H. Cardiac and respiratory function at rest in patients with uncomplicated polycythemia vera. Am J Med Sci. 1940;200:478-483. 266. Wanless IR, Peterson P, Das A, et al. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 1990;12:1166-1174[Medline]. 267. Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral blood-flow in polycythaemia. Lancet. 1977;2:161-163[Medline]. 268. Fiermonte G, Aloe Spiriti MA, Latagliata R, Petti MC, Giacomini P. Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial doppler. J Intern Med. 1993;234:599-602[Medline]. 269. York EL, Jones RL, Menon D, Sproule BJ. Effects of secondary polycythemia on cerebral blood flow in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;121:813-818[Medline]. 270. Brown MM, Wade JP, Marshall J. Fundamental importance of arterial oxygen content in the regulation of cerebral blood flow in man. Brain. 1985;108:81-93[Abstract]. 271. Wade JP. Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection. Brain. 1983;106:513523[Abstract]. 272. Brown MM, Marshall J. Regulation of cerebral blood flow in response to changes in blood viscosity. Lancet. 1985;1:604609[Medline]. 273. Wade JP, du Boulay GH, Marshall J, et al. Cerebral blood flow, haematocrit and viscosity in subjects with a high oxygen affinity haemoglobin variant. Acta Neurol Scand. 1980;61:210-215[Medline]. 274. Murray JF, Escobar E. Circulatory effects of blood viscosity: comparison of methemoglobinemia and anemia. J Appl Physiol. 1968;25:594-599[Medline]. 275. Massik J, Tang YL, Hudak ML, et al. Effect of hematocrit on cerebral blood flow with induced polycythemia. J Appl Physiol.

1987;62:1090-1096[Abstract/Free Full Text]. 276. Chien S, Usami S, Taylor HM, Lundberg JL, Gregersen MI. Effects of hematocrit and plasma proteins on human blood rheology at low shear rates. J Appl Physiol. 1966;21:81-87[Medline]. 277. Turitto V, Weiss H. Red blood cells: their dual role in thrombus formation. Science. 1976;207:541-543. 278. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821-828[Medline]. 279. Calabresi P, Meyer OO. Polycythemia vera I: clinical and laboratory manifestations. Ann Intern Med. 1958;50:1182-1216. 280. Dintenfass L. Viscosity of the packed red and white blood cells. Exp Mol Pathol. 1965;4:597-605[Medline]. 281. Kaplar M, Kappelmayer J, Kiss A, Szabo K, Udvardy M. Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts. Platelets. 2000;11:183-184[CrossRef][Medline]. 282. Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol. 1997;56:5-11[CrossRef][Medline]. 283. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:42614266[Abstract/Free Full Text]. 284. Posan E, Ujj G, Kiss A, et al. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res. 1998;90:51-56[CrossRef][Medline]. 285. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116-124[CrossRef][Medline]. 286. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol. 1991;95:82-86[Medline]. 287. Murphy S, Davis JL, Walsh PN, Gardner FH. Template bleeding

time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med. 1978;138:1251-1253[Medline]. 288. Lamparter S, Schuermann M, Heidtmann H-H. APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. Ann Hematol. 1997;74:4950[CrossRef][Medline]. 289. Gisslinger H, Rodeghiero F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 1999;105:551-555[Medline]. 290. Wiseman B, Rohn R, Bouroncle B, Myers W. The treatment of polycythemia vera with radioactive phosporus. Ann Intern Med. 1951;34:311-330. 291. Barach A, McAlpin K. Negative results of oxygen therapy in polycythemia vera. Am J Med Sci. 1937;185:178-181. 292. Bomchil G, Carmena A, Segade A, Cavagnaro F, De Testa N. Studies on the response to hypoxia and relative hyperoxia in two polycythemia vera patients. Ind J Med Res. 1967;55:543-548[Medline]. 293. Kaboth U, Rumpf KW, Lipp T, et al. Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis. Klin Wochenschr. 1990;68:18-25[Medline]. 294. Kutti J, Weinfeld A. Platelet survival in active polycythaemia vera with reference to the haematocrit level: an experimental study before and after phlebotomy. Scand J Haematol. 1971;8:405-414[Medline]. 295. Shaw D, Tudhope GR. Thrombocytosis, thrombocythaemia and iron deficiency in patients with polycythaemia vera. Acta Haematol. 1979;62:223-228[Medline]. 296. Challoner T, Briggs C, Rampling MW, Thomas DJ. A study of the haematological and haemorheological consequences of venesection. Br J Haematol. 1986;62:671-678[Medline]. 297. Segel N, Bishop JM. Circulatory studies in polycythemia vera at rest and during exercise. Clin Sci. 1967;32:527-549[Medline]. 298. Boughton BJ. Chronic myeloproliferative disorders: improved platelet aggregation following venesection. Br J Hematol. 1978;39:589598[Medline]. 299. Wehmeier A, Fricke S, Scharf RE, Schneider W. A prospective

study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol. 1990;45:191197[Medline]. 300. Boughton BJ, Dallinger KJ. 125I fibrinogen turnover in polycythaemia: the effect of phlebotomy. Br J Haematol. 1983;53:97102[Medline]. 301. Jackson DP. Hemorrhagic diathesis in patients with cyanotic congenital heart disease: preoperative management. Ann N Y Acad Sci. 1964;115:235-251. 302. Humphrey PR, Michael J, Pearson TC. Red cell mass, plasma volume and blood volume before and after venesection in relative polycythaemia. Br J Haematol. 1980;46:435-438[Medline]. 303. van Beaumont W, Greenleaf JE, Juhos L. Disproportional changes in hematocrit, plasma volume, and proteins during exercise and bed rest. J Appl Physiol. 1972;33:55-61[Medline]. 304. Rakita L, Gillespie DG, Sancetta SM. The acute and chronic effects of phlebotomy on general hemodynamics and pulmonary functions of patients with secondary polycythemia associated with pulmonary emphysema. Am Heart J. 1965;70:466-475[Medline]. 305. Wallis PJ, Skehan JD, Newland AC, et al. Effects of erythrapheresis on pulmonary haemodynamics and oxygen transport in patients with secondary polycythaemia and cor pulmonale. Clin Sci. 1986;70:91-98[Medline]. 306. Rosenthal A, Nathan DG, Marty AT, et al. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation. 1970;42:297-307[Medline]. 307. Weisse AB, Moschos CB, Frank MJ, et al. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med. 1975;58:9298[Medline]. 308. Milligan DW, MacNamee R, Roberts BE, Davies JA. The influence of iron-deficient indices on whole blood viscosity in polycythaemia. Br J Haematol. 1982;50:467-471[Medline]. 309. Hutton RD. The effect of iron deficiency on whole blood viscosity in polycythaemic patients. Br J Haematol. 1979;43:191-199[Medline]. 310. Rector WG, Fortuin NJ, Conley CL. Non-hematologic effects of

chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections. Medicine. 1982;61:382-389[Medline]. 311. Moore DF, Sears DA. Pica, iron deficiency, and the medical history. Am J Med. 1994;97:390-393[Medline]. 312. Pearson TC, Grimes AJ, Slater NG, Wetherley-Mein G. Viscosity and iron deficiency in treated polycythaemia. Br J Haematol. 1981;49:123-127[Medline]. 313. Birgegard G, Carlsson M, Sandhagen B, Mannting F. Does iron deficiency in treated polycythemia vera affect whole blood viscosity? Acta Med Scand. 1984;216:165-169[Medline]. 314. Yip R, Mohandas N, Clark MR, et al. Red cell membrane stiffness in iron deficiency. Blood. 1983;62:99-106[Abstract]. 315. Aarts PA, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood. 1983;62:214-217[Abstract]. 316. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233235[Medline]. 317. Hutt MSR. Polycythaemia with myelosclerosis. Proc R Soc Med. 1950;43:903-904. 318. Najean Y, Rain J. Treatment of polycythemia vera: use of 32P alone or in combination with maintenace therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood. 1997;89:23192327[Abstract/Free Full Text]. 319. Berlin NI, Lawrence JH, Gartland J. Blood volume in polycythemia as determined by P32 labeled red blood cells. Am J Med. 1950;9:747751. 320. Murray JF, Gold P, Johnson BL. The circulatory effects of hematocrit variations in normovolemic and hypervolemic dogs. J Clin Invest. 1963;42:1150-1159. 321. Pearson TC, Botterill CA, Glass UH, Wetherley-Mein G. Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values. Scand J Haematol. 1984;33:6874[Medline].

322. Pearson TC, Weatherly-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1221[Medline]. 323. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411418[Medline]. 324. Reid CD, Chanarin I, Lewis J. Formes frustes in myeloproliferative disorders: identification by the growth of an endogenous erythroid clone in vitro in patients with arterial vascular disease. Lancet. 1982;1:1415[Medline]. 325. Finch S, Haskins D, Finch CA. Iron metabolism hematopoiesis following phlebotomy iron as a limiting factor. J Clin Invest. 1950;29:1078-1086. 326. Reid J. Hemorrhagic thrombocythemia. Lancet. 1940;1:584-587. 327. Gunz F. Hemorrhagic thrombocythemia: a critical review. Blood. 1960;15:706-722. 328. Ozer F, Truax W, Miesch D, Levin W. Primary hemorrhagic thrombocythemia. Am J Med. 1960;28:807-823. 329. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23:172-176[Medline]. 330. Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol. 1982;50:157167[Medline]. 331. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients. Ann Hematol. 1991;63:101-106[Medline]. 332. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of platelet function in patients with polycythemia vera. Cancer Res. 1973;33:2683-2687[Medline]. 333. Randi ML, Casonato A, Fabris F, Vio C, Girolami A. The significance of thrombocytosis in old age. Acta Haematol. 1987;78:4144[Medline].

334. Williams EC, Shahidi NT. Benign familial thrombocytosis. Am J Hematol. 1991;37:124-125[Medline]. 335. Schlemper RJ, van der Maas AP, Eikenboom JC. Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol. 1994;68:153-158[Medline]. 336. Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. Am J Med. 1986;80:497-502[Medline]. 337. Cohen N, Almoznino-Sarafian D, Weissgarten J, et al. Benign familial microcytic thrombocytosis with autosomal dominant transmission. Clin Genet. 1997;52:47-50[Medline]. 338. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5'untranslated region of the thrombopoietin gene. Blood. 1998;92:10911096[Abstract/Free Full Text]. 339. Buss DH, Cashell AW, O'Connor ML, Richards F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247253[Medline]. 340. Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772-777[CrossRef][Medline]. 341. Arboix A, Besses C, Acin P, et al. Ischemic stroke as first manifestation of essential thrombocythemia. Stroke. 1995;26:14631466[Abstract/Free Full Text]. 342. Virmani R, Popovsky MA, Roberts WC. Thrombocytosis, coronary artery thrombosis and acute myocardial infarction. Am J Med. 1979;67:498-506[Medline]. 343. Johnson M, Gernsheimer T, Johansen K. Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. J Vasc Surg. 1995;22:443-449[Medline]. 344. Harrison CN, MacHin SJ. Antiphospholipid antibodies and essential thrombocythemia. Am J Med. 1997;102:317318[CrossRef][Medline]. 345. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive

factors in a series of 148 patients. Leukemia. 1999;13:150154[CrossRef][Medline]. 346. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;83:198-203[Medline]. 347. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemia: clinical evolutionary and biological data. Cancer. 1986;58:2440-2447[Medline]. 348. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549-556[Medline]. 349. Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 1993;82:1749-1757[Abstract]. 350. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol. 1996;93:962-965[Medline]. 351. van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol. 1997;99:832-836[Medline]. 352. Edwards E, Cooley MH. Peripheral vascular symptoms as the initial manifestation of polycythemia vera. JAMA. 1970;214:14631467[Medline]. 353. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23:441-454[Medline]. 354. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology. 1993;43:1107-1110[Abstract]. 355. Hussain S, Schwartz JM, Friedman SA, Chua SN. Arterial thrombosis in essential thrombocythemia. Am Heart J. 1978;96:3136[Medline]. 356. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood. 1992;80:19651971[Abstract].

357. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 1995;73:210214[Medline]. 358. Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood. 1998;91:1288-1294[Abstract/Free Full Text]. 359. Abdel-Naser MB, Gollnick H, Orfanos CE. Aquagenic pruritis as a presenting symptom of polycythemia vera. Dermatology. 1993;187:130133[Medline]. 360. Prentice TC, Berlin NI, Lawrence JH. Effect of therapy on blood volume, blood pressure, and spleen size in polycythemai vera. Arch Intern Med. 1952;89:584-590. 361. Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med. 1989;149:105-109[Medline]. 362. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69-76[Medline]. 363. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol. 1997;34:40-50[Medline]. 364. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94:1517-1536[Abstract/Free Full Text]. 365. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;1:39-47. 366. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-622[Abstract/Free Full Text]. 367. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4:197-201[Medline].

368. Conley CL. Polycythemia vera: diagnosis and treatment. Hosp Prac. 1987;22:181-210. 369. Handin RI, Lux SE, Stossel TP. Blood: Principles and Practices of Hematology 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2002.

Reprint (PDF) Version of this Article Email this article to a friend Similar articles found in: Blood Online PubMed PubMed Citation Search Medline for articles by: Spivak, J. L. Alert me when: new articles cite this article Download to Citation Manager Collections under which this article appears: Review Articles Clinical Observations, Interventions, and Therapeutic Trials Hematopoiesis Neoplasia All Versions of this Article: 100/13/4272 (most recent) 2001-12-0349v1

Blood Online is sponsored by an unrestricted grant from Shire